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1 Introduction 
1.1 The immune system 
The defence of multicellular organisms against invading pathogens is based on 
their ability to evoke immune responses. In vertebrates, the immune system has 
been divided into innate and adaptive components. The system of innate immunity 
is present in almost all multicellular organisms and provides the first line of 
defence. This non-specific response eliminates the majority of pathogens within 
minutes or hours. When these innate defences are breached the adaptive immune 
responses come into play. The adaptive immune system, which is only present in 
vertebrates, provides a more specific and long lasting protection. It recognizes 
complexes of peptide antigens and MHC-molecules on antigen presenting cells 
using antigen receptors expressed on the surface of T and B cells. The high 
viability of the antigen receptors is achieved by the random rearrangement of the 
immunoglobulin and T cell receptor genes. Antigen recognition initiates the 
production of antigen-specific antibodies or activation and proliferation of T cells. 
At least four to seven days are required to establish these responses. 
In contrast to the adaptive immune system, the phylogenetically older innate 
immune system detects invading microorganisms by recognizing a broad 
spectrum of universal microbial molecular patterns (Pathogen-associated 
molecular patterns (PAMPs)) via a limited repertoire of recognition molecules 
(Pattern recognition receptors (PRR)). These include several classes of receptors, 
such as the complement receptor, f-Met-Leu-Phe receptor, macrophage mannose 
receptor, scavenger receptors, CD14 and Toll-like receptors (TLRs). Particularly 
the discovery of the TLRs and of their involvement in the recognition of microbial 
components represented a milestone in the elucidation of the mode of action of 
innate immune responses. 
1.2 Toll-like receptors 
Toll receptors were originally identified in Drosophila by Nüsslein-Volhards 
group. These proteins are involved in the establishment of dorso-ventral polarity of 
the developing embryo [1] and anti-fungal immune response of the adult fly [2]. 
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Interestingly, the signaling pathways of Drosophila Toll and the mammalian IL-1 
receptor are remarkably similar and the cytoplasmic domains of both receptors 
highly conserved. These congruities lead to the identification of a family of 
mammalian homologues of the Toll protein, collectively denoted as Toll-like 
receptors (TLRs) [3]. Up to now, the TLR family consists of 11 members in 
mammals [4-9] and specificity for different ligands either resides within one 
receptor itself or is attained through heterodimerization (Figure 1.1).  
 
TLR1 TLR2 TLR6 TLR5 TLR11 TLR3 TLR9
triacyl-
LP MALP-2
LTA
LAM
... LPS Flagellin
profilin-
like
protein dsRNA
unmethylated
CpG DNA
ssRNA
small anti-
viral 
compounds
 
 
Figure 1.1 Toll-like receptors and their most prominent ligands 
 
Both, the IL-1 receptor (IL-1R) and TLRs contain an intracellular highly 
conserved region of about 200 amino acids denoted as TIR (Toll/IL-1R) domain 
[10]. The extracellular domains of both receptors, on the other hand are markedly 
different. Whereas the IL-1R possesses three immunoglobulin-like structures, the 
extracellular domains of TLRs form a horseshoe like structure. It is thought that the 
recognition of PAMPs is accomplished by the concave face of the horseshoe. This 
domain is derived of 19-25 tandem copies of leucine rich repeats (LRR) of 24 to 29 
amino acids each [11] containing the leucine-rich sequence XLXXLXLXX (where X 
can be any amino acid) (Figure 1.2). 
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TIR-domain
LRR
extracellular
intracellular
 
Figure 1.2 Structure of TLR 
 
1.2.1 TLR4 
TLR4 is the receptor for lipopolysaccharide (LPS), the main constituent of the 
outer cell membrane of Gram-negative bacteria. Prior to the identification of the 
receptor two mouse strains, C3H/HeJ and C57BL10/ScCr, had been known to be 
hypo-responsive against LPS. Later, it was shown, that both strains contain 
mutations in the Tlr4 gene leading to a non-functional receptor [12;13]. In addition 
to TLR4, several other molecules are involved in the LPS-dependent activation of 
cells. In serum, the highly amphiphatic LPS forms micelles which are recognized 
by LPS-binding protein (LBP). The acute phase protein accomplishes the transfer 
of monomeric LPS to CD14. CD14 is a 55 kDa glycoprotein of 356 amino acids 
that is expressed in a GPI-anchored and in a soluble form. The GPI-anchored form 
is expressed on cells of the myeloid lineage, i. e. monocytes, macrophages and 
polymorphonuclear granulocytes [14;15]. The soluble form (sCD14) plays a role in 
the LPS response of endothelial and epithelial cells [16-18]. The CD14 / LPS 
complex associates with TLR4 [19;20] leading to the activation of the receptor. 
Furthermore, MD-2, a molecule that is associated with the extracellular domain of 
TLR4 was found to directly bind to LPS and to amplify LPS responsiveness of cells 
[21;22].  
Several other PAMPs activate TLR4 in addition to LPS. These compounds 
include the anti tumor agent taxol [23], diverse classes of viruses [24;25], and 
endogenous ligands like heat shock proteins [26] and hyaluronic acid. It is 
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proposed that receptor agonists from endogenous origins, which are released from 
dead or injured cells, indicate an inflammatory process and therefore function as 
danger signals [27].  
1.2.2 TLR2 
TLR2 is characterized by the ability to recognize a wide variety of microbial 
components including lipoproteins [28-31], lipoteichoic acid [32], 
lipoarabinomannan [33], glycoinositolphospholipids [34], phenol-soluble modulin 
[35], zymosan [36], glycolipids [37], Neisseria outer membrane porins [38] and 
atypical LPS from Leptospira interrogans and Porphyromonas gingivalis [39;40]. 
For lipopeptide recognition TLR2 forms heterodimers with either TLR1 or 6. Both, 
the peptide moiety and the acylation pattern of the lipopeptide ligands determine 
the composition of the receptor dimer. Whereas triacylated lipopeptides are 
recognized by TLR2/TLR1 heterodimers [41] diacylated lipopeptides activate TLR2 
either in a TLR6-dependent [42] or -independent manner [43].  
CD14 is also involved in the activation of cells by lipopeptides as found for LPS. 
On the cell surface CD14 directly interacts with lipopeptides inducing a physical 
proximity of this complex with TLR2/TLR1 [44]. Since several other molecules 
were found to activate TLRs in a CD14-dependent manner (Chapter 2) CD14 is 
considered as a central PRR in innate immunity. 
1.2.3 Other TLRs 
TLR3, TLR7, TLR8 and TLR9 recognize nucleic acid-like structures and are 
localized in intracellular compartments. Unmethylated CpG motifs which are 
abundant in bacteria but absent in vertebrate DNA strongly activate immune cells 
through TLR9 [45]. Prior receptor activation DNA needs to be internalized into 
endosomal compartments where signal transduction is initiated [46]. For this 
reason TLR9-dependent activation of cells is delayed compared to LPS-induced 
activation [45]. 
The activation of TLR3, the receptor for viral double stranded (ds) RNA [47] 
induces a strong antiviral response via TLR3-dependent secretion of type I 
interferons (IFN-α and –β) by immune cells. Synthetic dsRNA analogues, such as 
polyinosinic-polycytidylic acid [poly(I:C)] showed comparable agonistic activity and 
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have found application as adjuvants in vaccinations. TLR7 and 8 recognize single 
stranded RNA [48;49] and several synthetic antitumor compounds including 
imidazoquinolines [50;51]. In addition, the activation of immune cells by RNA 
complexed with protamine is probably accomplished in a TLR7- and 8-dependent 
manner [52]. TLR5 recognizes flagellin, a complex protein of flagellar extending 
from the cell wall of Gram-negative bacteria [53] and TLR11 responds to a 
protozoan profilin-like protein [54]. The ligand of TLR10 has yet not been 
identified. So far, TLR1 and TLR6 were only identified as co-receptors for TLR2 
(Table 1.1). 
 
Table 1.1 Toll-like receptors and their ligands 
Receptor Ligand Origin 
TLR1 
(coreceptor) 
Triacyl lipopeptides Bacteria and mycobacteria 
TLR2 Lipoproteins/lipopeptides 
Peptidoglycan 
Lipoteichoic acid 
Lipoarabinomannan 
Phenol-soluble modulin 
Glycoinositolphospholipids 
Glycolipids 
Porins 
Atypical lipopolysaccharide 
 
Zymosan 
Various pathogens 
Gram-positive bacteria 
Gram-positive bacteria 
Mycobacteria 
Staphylococcus epidermidis 
Trypanosoma cruzi 
Treponema maltophilum 
Neisseria species 
Leptospira interrogans 
Porphyromonas gingivalis 
Fungi 
TLR3 Double-stranded RNA Viruses 
TLR4 Lipopolysaccharide 
Taxol 
Heat-shock protein 
Gram-negative bacteria 
Plants 
Host 
TLR5 Flagellin Bacteria 
TLR6 
(coreceptor) 
Diacyl lipopeptides 
Lipoteichoic acid 
Zymosan 
Mycoplasma 
Gram-positiv bacteria 
Fungi 
TLR7/8 Single-stranded RNA 
Imidazoquinoline 
Viruses 
Synthetic compound 
TLR9 CpG-containing RNA Bacteria and Viruses 
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TLR10 unknown unknown. 
TLR11 protozoan profilin-like protein Uropathogenic bacteria 
 
1.3 TLR signal transduction 
1.3.1 Signal transduction  
The interaction of a TLR with its ligand leads to the transcriptional activation of 
the synthesis of inflammatory cytokines, chemokines, reactive oxygen species, 
and acute phase proteins primarily mediated by the transcription factor NF-κB. 
The first event in the TLR-dependent signaling cascade is the recruitment of the 
adaptor molecule MyD88 to the cytoplasmic domain of the activated receptor [55]. 
The receptor-bound MyD88 itself recruits the death domain containing 
serine/threonine-kinase IRAK4 resulting in the activation of the kinase. MyD88 
contains a C-terminal TIR and an N-terminal death domain and the interactions 
are accomplished through homologous TIR/TIR and death/death domain 
dimerizations, respectively [56]. IRAK4 then binds and activates IRAK1 which itself 
recruits a further adaptor molecule, TRAF6 [57], to the complex. This association 
is mediated by the binding of TRAF6 to autophosphorylated residues of IRAK1. 
Subsequently, the IRAK1/TRAF6 heterodimer dissociates from the receptor 
complex and associates to a complex of the mitogen-activated protein kinase 
kinase kinase (MAPKKK), TAK1 and the adaptor molecules TAB1, and TAB2 or 
TAB3 at the plasma membrane. The binding eventually leads to the translocation 
of the entire complex to the cytoplasm where TAK activates the inhibitor-κB kinase 
(IKK) complex. This complex is composed of two catalytic subunits, IKKα and 
IKKβ, and the scaffold protein, IKKγ/NEMO [58]. The activated kinases 
phosphorylate inhibitor-κB thereby releasing the inhibitory effect of this protein on 
NF-κB and initiating the nuclear translocation of the transcription factor. In the 
nucleus, NF-κB binds to NF-κB-promotor regions and initiates gene transcription 
[59]. In addition, TAK1 contribute to the activation of MAPKs.  
The activation of macrophages by LPS is not strictly dependent on MyD88. 
Studies with MyD88-deficient macrophages revealed the existence of a MyD88- 
independent pathway which also results in NF-κB activation [60], however 
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retarded in comparison to the MyD88-dependent pathway. The MyD88-
independent pathway is responsible for the induction of the expression of IFN-
inducible genes [61]. In contrast to LPS, lipopeptides activate cells only in a 
MyD88-dependent manner.  
Several other TIR domain-containing adaptor molecules are involved in TLR-
dependent signaling in addition to MyD88 and TRAF6. TIRAP (TIR domain-
containing adaptor protein/MyD88-adaptor-like (Mal)) is essential for the MyD88-
dependent activation mediated by TLR2 and TLR4 [62] whereas the MyD88-
independent pathway is dependent on the adaptor molecules TRAM [63] and TRIF 
[64]. TRAM interacts with the cytoplasmic domain of TLR4 and recruits TRIF to the 
complex.  
The utilization of several adaptor molecules in the TLR-dependent signal 
transduction enables ligand-specific responses. The synergistic activation of both 
the MyD88-dependent and MyD88-independent/TRIF-dependent pathways by 
TLR4 stimulation is a possible explanation for the outstanding immune-stimulating 
properties of LPS [65]. 
1.3.2 Negative Regulation  
Several molecules, such as TOLLIP, IRAK-M, MyD88s, SIGGIR and ST2 are 
involved in the negative regulation of the TLR-dependent signal transduction. In 
resting cells, TOLLIP suppresses the phosphorylation of IRAK1 by binding to the 
kinase. After receptor stimulation, TOLLIP dissociates from IRAK1 and eventually 
interacts with the TIR domain of TLR2 and TLR4. IRAK1 then becomes accessible 
for activation [66].  
IRAK-M is an IRAK-family member that lacks a kinase activity. This molecule 
inhibits the dissociation of the IRAK1-IRAK4 complex from MyD88 [67]. MyD88s, 
an alternatively spliced variant of MyD88, is expressed in LPS stimulated 
lymphocytes. After TLR stimulation MyD88s binds to the cytoplasmic domain of 
TLRs, but fails to bind to IRAK4 [68]. The TIR domain containing proteins, SIGGIR 
[69] and ST2 [70], inhibit the TIR-dependent signaling pathways by interacting with 
TLR4, IRAK1 and TRAF6 or  MyD88 and TIRAP, respectively. 
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 1.4 Regulation of adaptive immuniy 
It is proposed that without the assistance of the innate immunity an appropriate 
activation the adaptive immune system is not possible. Dendritic cells (DCs), that 
express a variety of TLRs [71] play a central role in the activation of adaptive 
immunity. In the periphery, immature DCs are exposed to a multitude of microbial 
compounds which they engulf by endocytosis. Digested fragments of these 
pathogens are returned to the cell surface in complex with class II 
histocompatibility molecules. The activation of the TLRs on the surface of DCs 
provides the signal for the expression of cytokines including IL-6 and co-
stimulatory molecules, such as B7, necessary for the appropriate activation of T 
cells. Several other molecules expressed on the surface of or secreted by DCs 
such as chemokine receptors, the co-stimulatory molecules CD80/CD86 or IL-12 
contribute to an efficient activation of the cells of the adaptive immunity [72].  
1.5 Bacterial cell wall 
Based on the property of the bacterial cell wall to differently retain the dye 
crystal violet during solvent treatment, bacteria were divided in Gram-positive and 
–negative species. Whereas Gram-negative bacteria lose the dye during solvent 
treatment, Gram-positive bacteria remain coloured. Differences in the composition 
of the cell wall are responsible for these characteristics. The cell wall of Gram-
positive bacteria is composed of various layers of peptidoglycan (PGN) in which 
crystal violet dye primarily accumulates. PGN consists of altering N-
acetylglucosamine- and N-acetylmuraminic acid units to which other molecules, 
such as LTA, LAM, lipopeptides and –proteins are connected. Whereas the cell 
wall of Gram-positive bacteria consists of about 60% to 90% PGN, the cell wall of 
Gram-negative bacteria contains only 10 to 20% PGN. In Gram-negative bacteria, 
a single layer of PGN is enclosed by a periplasmatic space and an outer 
membrane.  
The outer leaflet of the outer membrane is mainly composed of LPS 
(approximately 3.5 x 106 molecules per E. coli cell) which contributes to the 
stability of the cell wall. The amphiphatic LPS can be divided into four different 
parts: the lipid A, inner and outer core and the O-antigen (Figure 1.3). Lipid A, the 
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lipid portion of LPS, is essential for the immune-stimulating activities (Galanos 
1985; Raetz, 1990). In Lipid A, six or more fatty acid residues of which four are 
hydroxylated are bound to a phosphorylated glucosamine disaccharide. The 
second portion of LPS, the inner core, is covalently linked to the lipid A 
glucosamine residue and consists of two or more 2-keto-3-deoxyoctonic acid 
(KDO) residues and two or three heptose sugars. The outer core is more variable 
than the inner core and usually composed of three sugars to which one or more 
sugars are linked as side chains. The O-antigen is characterized by a high 
variability and extents from the bacterial surface. It is composed of 20 to 40 
repeating units each of five common sugars. Colonies of bacteria with O-antigen 
containing LPS exhibit a smooth morphology whereas those of bacteria with an O-
antigen lacking LPS have a rough surface texture. For this reason, LPS with O-
antigen is denoted as smooth-LPS (S-LPS), the O-antigen lacking as rough–LPS 
(R-LPS). Based on its composition, R-LPS can be divided into several serotypes. 
For instance, R-LPS consisting only of lipid A and the inner core is denoted as Rd-
LPS, whereas Ra-LPS is composed of lipid A, inner and outer core. 
To exert their immune-stimulating properties LPS and other PAMPs have to be 
released from the bacterial cell wall triggered by bacterial death or growth and 
endogenous or exogenous factors such as complement or several antibiotics. 
 
 
 
 
 
 
 
 
Figure 1.3 Structure of LPS 
1.6 Lipoproteins and -peptides 
Bacterial lipoproteins are constituents of the outer membrane of Gram-negative 
bacteria, Gram-positive bacteria and mycoplasma [73-75]. A common feature of 
lipopeptides from different bacteria is the N-terminal posttranslationally modified 
amino acid S-[2,3-dihydroxypropyl]-cysteine which carries covalently linked long 
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chain fatty acids at the amino-terminus and on both hydroxy groups of the 1,2-
dihydroxypropyl group. In contrast to the lipid part, the protein moieties of different 
lipoproteins show no conspicuous sequence homology. The most prominent 
member of this class of molecules is Braun’s lipoprotein of 7200 Da which 
represents the major constituent of the periplasmic space of the cell wall of 
enterobacteriaceae (Figure 1.4).  
R1 R2 R3
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L-Ala
D-Glu
Lys-NH2
COOH
-GlcNAc-MurNAc-......-GlcNAc-MurNAc
O
outer membrane
cytoplasmic membrane
O NH
m -NH-A pm2 2
(aa)56
CH -CH-CH - -Cys2 2 S
 
 
Figure 1.4 Composition and localization of Braun’s lipoprotein (m-A2pm-NH2, meso-
diaminopimelic acid; GlcNAc, N-acetylglucosamine; MurNAc, N-acetylmuraminic acid) 
 
The hydrophobic N-terminus of this lipoprotein is imbedded into the bilayer of 
the outer membrane whereas the protein part is covalently or non-covalently 
associated with the peptidoglycan accomplishing a tight linkage between the 
murein and the membrane. 
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Figure 1.5 Structure of (A) lipopeptides and (B) Pam3Cys-SerLys4 
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Lipoproteins exhibit strong cell stimulating properties in vivo and in vitro 
including NF-κB activation, cytokine release, and B cell growth [76-81]. However, 
these immune stimulatory activities were not restricted to naturally occurring 
lipoproteins. Also synthetic lipopeptides containing only few amino acids have 
been shown to be efficient immune activators [79]. Because of their immune-
stimulating properties and the absence of toxic side effects [82] lipopeptides attain 
relevance as adjuvant in vaccinations [83]. For instance, the application of 
Pam3Cys-Ser-Ser covalently linked as adjuvant in a peptide-based vaccine against 
the foot-and-mouth disease virus provided a long-lasting protection [84]. A 
conjugate of lipopeptide, hapten and haplotype-specific T helper-cell epitope was 
able to evoke hapten-specific immune responses [85]. Moreover, synthetic 
lipopeptide conjugates containing MHC class I restricted peptides were able to 
efficiently prime virus-specific cytotoxic T cells [86]. The water soluble lipopeptide 
Pam3Cys-SerLys4 was shown to induce an immunostimulatory activity that is 
comparable to that of the complete Freunds Adjuvant (CFA).  
Since lipopeptides are accessible by established synthesis protocols [79;80;87-
93] and in high purity they are excellent candidates for investigations of the 
structure-activity relationships of TLR agonists. Spohn et al. [94] investigated 
whether either variations in the peptide moiety, S-[2,3-dihydroxypropyl]-cysteine 
scaffold, or length and amount of the fatty acids of lipopeptides influences the 
activity of these molecule. For the peptide moiety a length of at least two amino 
acids is essential for activity whereas the sequence of the peptide has almost no 
influence on the agonistic properties. For triacylated lipopeptides the biological 
activity was dependent on the length of the fatty acids and a reduction to ten and 
less carbon-atoms for each fatty acid resulted in a less active analogue. However, 
lipopeptides that contain only one fatty acid completely lost their immune-
stimulating properties. Furthermore, agonistic activity was dependent on the 
presence of the sulfur atom in the S-[2,3-dihydroxypropyl]-cysteine scaffold and on 
the configuration of the two stereocenters of the lipoamino acid Pam3Cys. RR-
stereoisomers corresponding to the configuration of the natural N-terminal lipo-
amino acid S-[2,3-bis(palmitoyloxy)-(2R)-propyl]-N-palmitoyl-(R)-cysteine of the 
bacterial lipoprotein of di- and triacylated lipopeptides are more active as agonists 
or adjuvants than the mixture of stereoisomers containing S-[2,3-bis(palmitoyloxy)-
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(2RS)-propyl]-N-palmitoyl-(R)-cysteine or only the S-[2,3-bis(palmitoyloxy)-(2S)-
propyl]-N-palmitoyl-(R)-cysteine stereoisomer [83;84;95].  
1.7 Sepsis and septic shock 
Sepsis is defined as a “systemic inflammatory response syndrome that occurs 
during infection” [96]. It represents an uncontrolled inflammatory response of the 
host against invading microorganisms and can lead to a life-threatening condition 
called septic shock. Paradoxically, due to the improved medical support, 
represented by invasive equipment, chemotherapy and immune suppression in 
patients, the cases of sepsis and septic shock have dramatically increased over 
the last decades. For instance, in the United States there are an estimated 
750,000 new cases annually leading to about 200.000 cases of death [97]. 
Depending on the study Gram-negative bacteria were responsible for about 30 
and 80%, Gram-positive bacteria for 6 and 24% of all cases of sepsis [98].  
Due to pronounced complexity of the biochemical processes that precede sepsis 
and septic shock treatment is difficult to carry out. Bacterial compounds trigger the 
release a multitude of inflammatory mediators from cells of the innate immune 
system. These mediators are responsible for a number of systemic changes, such 
as vasodilatation, extravasations of neutrophils and monocytes, activation of 
leukocytes, lymphocytes and endothelial cells, myocardial suppression, 
microvascular coagulation, hypoperfusion, hypoxia and apoptosis. These 
conditions can result in the failure of organ function and finally in the death of the 
patients. 
For the treatment of sepsis scientists have focussed on the identification of 
agents that interfere with components contributing to the initiation and progress of 
the disease. These components include bacterial products, early host 
inflammatory cytokines, bioactive lipid mediators, NO, endogenous 
immunostimulatory molecules, coagulation components, receptors and molecules 
involved in the TLR-dependent signal transduction [99]. Several agents have 
already been conducted in clinical trials such as corticosteroids [100], anti-
endotoxin antibodies [101], TNF-α antagonists [102;103], IL-1 receptor antagonists 
[104] and recombinant activated protein C [105]. However, up to now only 
activated protein C has found application in the clinic [99] (Table 1.2). 
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Table 1.2 Selection of potential sepsis and septic shock therapies 
Target Drug Comment 
Monoclonal α-lipid A 
antibody HA-1A 
HA-1A: Reduced mortality in patients with 
Gram-negative sepsis but increased mortality in 
septic patients without Gram-negative 
bacteraemia [101]. In vitro studies revealed that 
HA-1A insufficiently neutralize endotoxin 
BPI 
21-kDa peptide (rBPI21) 
Modest reduction of mortality in human sepsis 
(Phase III) [106] 
cationic antimicrobial 
protein 18 kDa (CAP18) 
Biological activity in preclinical studies [107] 
Polymyxin-B-dextran 
conjugate 
No benefit (Phase II, not published) 
E5531 
 
Synthetic endotoxin antagonist [108] 
Polyvalent 
immunoglobulin 
(intravenous 
immunoglobuline (IVIG)) 
Concentrated immunoglobulin from multiple 
donors enabled a significant mortality benefit 
Endotoxin 
Soluble TLR4 Inhibited LPS-mediated TNF-α secretion in mice 
[109]   
α-TLR2 antibody 
(T2.5) 
Antagonistic antibody against the extracellular 
domain of TLR2. Inhibition of lipopeptide-
induced TNF-α release in mice [110]  
Toll-like receptors 
Hydrocinnamoyl-L-valyl 
pyrrolidine  
Blocks the Intracellular TIR-TIR domain 
interaction, thereby inhibiting IL-1-induced fever 
response [111]  
TNFR-Fc-fusion proteins 
of p55 and p75 
p55 had no benefit in human sepsis and p75 
was harmful [102;112] 
α-TNF antibodies Effective in primates and mice but ineffective in 
humans [113] 
Inflammatory 
cytokines 
Recombinant IL-1 
receptor antagonist (IL-
1ra) 
Small mortality benefit in human sepsis [104] 
Lipid mediators 
Phosphlipase A2, 
sPLA2  
small molecule inhibitor 
No benefit 
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Platelet-activating 
factor 
(Ly315920) and synthetic 
PAF receptor antagonist 
Prostaglandins Ibuprofen No benefit 
Inducible nitric oxid 
synthase (iNOS) 
L-N-monomethyl arginine 
(L-NMMA) N-omega-
nitro-L-arginine methyl 
ester (L-NAME) 
L-NMMA was harmful due to increase in blood 
pressure 
Recombinant activated 
protein C 
(rAPC) 
Significant reduction of mortality [105], due to 
decreases of inflammation by inhibition of 
platelet activation, neutrophil recruitment, and 
mast-cell degranulation, cytokine release in 
monocytes and adhesive interactions between 
neutrophils and endothelial cells. 
Despite of the induction of serious bleeding 
rAPC is the first drug for treatment of patients 
with severe sepsis in the clinic 
Coagulation  
Antithrombin III No benefit 
Blood glucose Insulin Lowers mortality rate by an unknown 
mechanism 
IFN-γ Immune enhancing therapy is beneficial in the 
hypo-immune phase of sepsis which occurs 
often prior death of the patients [114] 
Immune response 
Corticosteroids physiological doses could improve survival 
(Phase III) [115] but large doses enhanced 
mortality in human sepsis  
 
The failure to efficiently reduce the mortality rate of septic shock might be due to 
the outstanding relevance of the innate immune system. A total blockage of its 
components has found to be contraindicative. For instance, when soluble TNF-
receptors were administered at high doses in patients with sepsis an increased 
mortality rate was observed [102]. This is in accordance with results from 
experiments with C3H/HeJ mice. The complete loss of TLR4 of these mice also 
led to an increased mortality rate after S. typhimurium challenge [116].  
One important strategy for the treatment of sepsis constitutes the neutralization 
of PAMPs responsible for the initiation and progress of the disease. One factor 
that results in the increased release of PAMPs from the bacterial cell wall is the 
application of antibiotics for treatment of patients with bacteraemia. Especially 
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antibiotics of the β-lactam type [117] exhibit lytic properties against bacterial cells 
leading to enhanced endotoxin concentrations in serum [118]. For this reason, 
various investigations have focused on the identification of agents capable of 
neutralizing endotoxin. Several agents, including anti-LPS antibodies, LPS-binding 
proteins, peptides and lipopeptides have shown to neutralize endotoxin in vivo and 
in vitro. For instance, bactericidal permeability-increasing protein (BPI) a 55 kDa 
protein secreted from neutrophils and the lipopeptide antibiotic polymyxin B [119] 
exhibit strong LPS-neutralizing capacity [120]. Peptides with antimicrobial activity 
and especially those of the group of cationic α-helical peptides often possess LPS-
neutralizing activity in addition to their lytic properties.  
1.8 Antimicrobial peptides 
Antimicrobial peptides are produced by vertebrates, invertebrate and plants and 
constitute an important component of the innate immune system. Among them 
peptides with cationic, amphipathic structures are particularly abundant and up to 
now, more than 500 natural occurring peptides of this class have been identified. 
Based on their structure cationic antimicrobial peptides can be divided into four 
different groups: α-helical, β-sheet, loop, and extended peptides [121] (Table 1.3) 
 
Table 1.3 Several types of cationic antimicrobial peptides. 
 
The antimicrobial activity of those peptides is based on the property to interact 
with bacterial membranes [121]. This binding is mediated by electrostatic 
interactions between cationic charges of the peptide and the negatively charged 
Peptide Class Host Sequence 
LL-37 
(CAP18) 
α-helical Human  LLGDFFRKSKEKIGKEFKRIVYRIKDFLRNLVPRTES
Tachyplesin-
1 
β-sheet Horseshoe 
crab 
KWCFRVCYRGICYRRCR 
 
Thanatin loop Spinded 
soldier 
bug 
GSKKPVPIIYCNRRTGKCQRM 
 
Indolicidin extended Bovine ILPWKWPWWPWRR 
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LPS in the outer leaflet of the outer membrane of the bacterial cell wall. Thereby 
the peptides displace divalent cations from LPS resulting in the destabilization of 
the membrane structure and translocation into the bacterium. This process is 
called self-promoted uptake. Subsequently peptides breach the cytoplasmic 
membrane in a disruptive or non-disruptive manner. Most cationic α-helical 
antimicrobial peptides exhibit membrane disruptive properties and three models 
have been described: the barrel stave, the micellar aggregate and the carpet 
model. In the barrel-stave model [122;123], the amphipathic peptides form 
transmembrane pores which destroy the membrane potential and enable leakage 
of cytoplasmic components. Within the pores the hydrophobic side chains of the 
peptides face into the lipid environment whereas the polar side chains point 
inwards into the pores [124]. In the micellar aggregate model the peptides form 
micelles or aggregates inside the membrane [125]. The translocation of the 
peptides into the cytoplasm is accomplished by collapse of these structures. In the 
carpet model, peptides arrange parallel to the bilayer without intruding into the 
membrane [126]. This arrangement results in a local disturbance of membrane 
stability leading to the disruption of the membrane potential, the disintegration of 
the membrane and followed by leakage of cytoplasmic components.  
1.8.1 α-Helical peptides 
A considerable number of α-helical antimicrobial peptides and their synthetic 
derivatives possess LPS-binding and –neutralizing activity [127-129]. The α-helix 
structure is often interrupted by a bend in the centre of the molecule. Magainins 
are α-helical peptides from Xenopus laevis [130] which possesses antimicrobial 
activities at concentrations 50 µg/ml against E. coli. It was shown that the 23-
peptide magainin 2 uses the the micellar-aggregate model for bacterial killing 
[125]. As determined by investigations of the structure-activity relationships of 
magainins, this activity was dependent on both, the length and the positive net 
charge of the peptide. Truncation to fewer than 20 residues led to a loss in activity 
due to the disability of the shorter analogue to span the lipid bilayer [131] whereas 
the enhancement of total net charge led to an increase in antimicrobial activity 
[132].  
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Alamethicin, isolated from the fungus Trichoderma viride [122;133], is a well 
characterized α-helical peptide with antimicrobial activity. In membranes, synthetic 
analogues of alamethicin form circular oligomeric bundles [134] following the 
barrel stave mechanism. This leads to the formation of a large number of small 
potential dependent channels of varying size allowing the leakage of ions at nM 
concentrations and lysis of cells at µM concentrations.  
1.8.2 β-Sheet peptides 
β-Sheet peptides possess an antiparallel β-sheet structure stabilized by disulfide 
bonds. Tachyplesins are peptides with 17-18 residues of this class isolated from 
the haemocytes of the Japanese horseshoe crab, Tachypleus tridentatus [135]. 
Because linearization of the peptides results in a loss of function, the β-sheet 
structure is a prerequisite for activity. The mode of action, however, is poorly 
understood and, despite of their high affinity for LPS [136], it is thought that 
Tachyplesins also address intracelluar targets [137].  
1.8.3 Extended peptides 
Because of their high proline and/or glycine content extended peptides do not 
exhibit classical secondary structure. These peptides interact with membrane 
lipids via hydrogen bond and van der Waals interactions. Indolicidin, isolated from 
granules of bovine neutrophils has the highest known content of tryptophan of all 
naturally occurring peptides [138;139]. To exhibit antimicrobial activity (10 µg/ml) 
the 13-peptide forms feature less aggregate channels which lead to a translocation 
of the peptide into the cytoplasm. In contrast, it does not have a high affinity for 
LPS compared to tachyplesins [140].  
1.8.4 Loop peptides 
Loop peptides such as the 21-residue peptide Thanatin, isolated from spined 
soldier bug Podisus maculiventris [141] are characterized by a loop structure, 
stabilized by disulfide, amide or isopeptide bonds. Thanatin possesses an 
antimicrobial activity against Gram-negative and –positive bacteria as well as 
INTRODUCTION 
_________________________________________________________________________ 
 
18 
activity against fungi. For granmycin S, another member of this family, also LPS-
neutralizing capacity was observed [142]. 
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2 A CD14 domain with LPS-binding and –neutralizing activity 
This chapter was adapted from a manuscript accepted for publication in 
ChemBioChem. The author of this thesis performed all experiments except site 
directed mutagenesis.   
2.1 Summary 
The 55 kDa protein CD14 binds to lipopolysaccharide (LPS) and several other 
bacterial cell wall components. CD14 plays a central role in TLR2- and TLR4-
mediated signaling in the innate immune response. To identify the structural 
determinants involved in ligand recognition synthetic peptides of 20 amino acids 
covering the complete CD14 sequence with ten amino acids overlap were tested 
for their potential to neutralize the LPS-dependent induction of IL-8 secretion in 
human myelomonocytic THP-1 cells. The peptide CD14 (81-100) exhibited a 
strong neutralizing activity, which was demonstrated to be based on its ability to 
bind to LPS. A detailed analysis of the structure-activity relationships revealed a 
set of aliphatic residues involved in binding that are highly conserved among CD14 
proteins from different species. Mutant proteins, in which the relevant residues 
were exchanged, failed to bind LPS in cellular experiments. Circular dichroism 
spectroscopy showed that the peptide assumed an α-helical secondary structure 
under mild helix-inducing conditions. Peptides corresponding to the structural 
determinants of LPS-binding proteins are potential agents for interfering with the 
initiation of LPS-mediated immunological disorders, such as septic shock. 
Therefore analogues of the CD14-derived LPS-binding peptide were synthesized 
with improved solubility and inhibitory activity in cellular assays and in the Limulus 
amebocyte lysate assay. In summary, our results confirm that this domain and 
especially leucine residues 87, 91 and 94 contribute to the LPS-binding site of 
human CD14. The corresponding peptides constitute a basis for the generation of 
LPS-neutralizing agents. 
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2.2 Introduction 
Lipopolysaccharide (LPS) is a highly potent immune stimulatory component of 
the cell wall of Gram-negative bacteria. Low concentrations in blood lead to 
moderate immune responses in healthy humans, whereas higher concentrations 
may induce massive release of cytokines, resulting in life threatening disorders 
such as septic shock [143]. Once released from the bacterial cell wall, LPS is 
sequestered by the serum protein lipopolysaccharide-binding protein (LBP), which 
transfers LPS to CD14 [144;145]. CD14 is a 55 kDa glycoprotein of 356 amino 
acids (Figure 2.1) that is expressed in a GPI-anchored and in a soluble form.  
 
       -10         01         11         21         31         41  
         |          |          |          |          |          |  
MERASCLLLL LLPLVHVSAT TPEPCELDDE DFRCVCNFSE PQPDWSEAFQ CVSAVEVEIH 
 
        51         61         71         81         91        101  
         |          |          |          |          |          |  
AGGLNLEPFL KRVDADADPR QYADTVKALR VRRLTVGAAQ VPAQLLVGAL RVLAYSRLKE  
 
       111        121        131        141        151        161  
         |          |          |          |          |          |  
LTLEDLKITG TMPPLPLEAT GLALSSLRLR NVSWATGRSW LAELQQWLKP GLKVLSIAQA  
 
       171        181        191        201        211        221  
         |          |          |          |          |          |  
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       231        241        251        261        271        281  
         |          |          |          |          |          |  
CAALAAAGVQ PHSLDLSHNS LRATVNPSAP RCMWSSALNS LNLSFAGLEQ VPKGLPAKLR  
 
       291        301        311        321        331        341  
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       351  
         |  
VSGTLVLLQG ARGFA 
 
Figure 2.1 Amino acid sequence of human CD14. The mature glycoprotein has a molecular 
weight of 55 kDa and consists of 356 amino acids. The signal peptide comprises 19 amino acids 
(grey). The protein is characterized by a high leucine content (17.7%) and eleven leucine-rich 
repeats of 21 to 36 residues which are located within the C-terminal part (residue 73 to 349). LRR 1 
contains 29 amino acids and is underlined in the sequence. 
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The GPI-anchored form is preferentially expressed on cells of the myeloid 
lineage, i. e. monocytes, macrophages and polymorphonuclear granulocytes 
[14;15]. The soluble form (sCD14) plays a role in the LPS response of endothelial 
and epithelial cells [16-18]. The endotoxin-CD14 complex engages Toll-like 
receptor 4 (TLR4) [12], initiating an intracellular signaling cascade and the 
expression of genes involved in the regulation of the immune response. 
In addition to LPS, CD14 binds a panel of components of Gram-negative and -
positive bacteria which are implicated in the initiation of TLR2-dependent signal 
transduction. These components include lipoarabinomannan of Mycobacterium 
tuberculosis [146;147], peptidoglycan [148], lipoteichoic acid [149], and spirochetal 
outer membrane lipoproteins and lipopeptides [150]. For this reason, CD14 was 
defined as a pattern recognition receptor in innate immunity [147].  
Because of this central role, several studies have focused on the identification of 
structural elements in CD14 involved in ligand recognition and binding. It was 
shown, that the N-terminal part comprising amino acids 1-152 is sufficient for 
binding and for enabling cellular responses to LPS, both for the soluble and the 
membrane-bound form [151;152]. Hydrophilic regions and amino acids within the 
N-terminal portion were identified for serum-dependent binding of LPS to CD14 by 
constructing a series of single and combined deletion mutants of membrane-
anchored CD14 [153]. However, only one of these mutations affected the LPS-
binding of sCD14 in a further study [154]. Due to these discrepancies, the authors 
proposed that different structural determinants may contribute to LPS receptor 
function for the soluble and the membrane-anchored forms of CD14. The 
involvement of individual hydrophilic amino acids within the N-terminal 66 amino 
acids in binding soluble CD14 to LPS was further investigated by serine 
replacement and charge reversal [155;156]. However, only charge reversal of 
amino acid side chains abolished the function of the protein. Amino acids 57 to 64 
were protected by LPS from the action of Asp-N protease and chymotrypsin and 
deletion of this particular region resulted in a non-functional mutant which neither 
bound LPS nor triggered cellular responses to LPS [157;158]. Evidence for a 
contribution of amino acids 39 to 44 to LPS-binding was obtained from a mutant in 
which all amino acids were exchanged by a stretch of alanine residues [159]. 
Alternatively, a further study suggested that the LPS-binding site might be a 
conformational epitope comprising several other regions of the protein [160]. 
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Furthermore, one report showed that amino acids 9 to 13 and 91 to 101 participate 
in sCD14-mediated signaling, however, not for all of the tested immunologically 
relevant cell types [161].  In summary, in spite of these investigations, many 
questions on the function of CD14 still remain. 
Synthetic peptides covering parts of a protein represent an alternative strategy 
for the identification of ligand-binding domains. Peptides derived from Tachypleus 
anti-LPS factor [162], Limulus anti-LPS factor (LALF) [163;164], 
bactericidal/permeability increasing protein (BPI) [165], human cationic 
antibacterial protein of 18 kDa (hCAP18) [107;128], lactoferrin [166], LBP [167], 
and the lipopeptide antibiotic polymyxin B [168] have been identified as endotoxin-
binding and -neutralizing agents. A structural comparison of these LPS-binding 
peptides and further analyses of structure-activity relationships showed that an 
amphiphilic structure with a net positive charge as well as a considerable 
hydrophobicity are a general characteristic of these molecules. The spatial 
organization of the positive and hydrophobic moieties largely determines the LPS-
binding and -neutralizing activity [169-171]. It can be assumed that the positively 
charged amino acid residues interact with the negatively charged moieties of the 
LPS such as the phosphate groups whereas hydrophobic amino acids may bind to 
the fatty acid chains of LPS [172].  
LPS-binding peptides might possess potential as drugs for the treatment of 
sepsis and septic shock [127;128;173] and for the generation of affinity reagents 
for the removal of LPS from the blood stream [174]. Analyses of structure-activity 
relationships of such peptides that contribute to an understanding of the mode of 
binding are therefore highly relevant for the generation of optimized LPS-
neutralizing agents. 
To identify structural determinants of CD14 involved in LPS-binding a systematic 
peptide-based approach using 20-peptides with 10 amino acids overlap that 
covered the complete mature protein was performed. 20-Peptides are sufficiently 
long to form secondary structure elements corresponding to those formed in full 
length proteins [175]. Initially all peptides were screened for their ability to 
antagonize the LPS-induced IL-8 secretion in THP-1 cells. The rather hydrophobic 
peptide corresponding to amino acids 81 to 100 had a strong inhibitory activity. 
This activity was attributed to a direct interaction of the peptide with LPS. Detailed 
analyses of structure-activity relationships revealed that leucine residues are 
A CD14 DOMAIN WITH LPS-BINDING AND –NEUTRALIZING ACTIVITY 
_________________________________________________________________________ 
 
23
required of this inhibitory activity. The relevance of the respective residues for 
ligand recognition by the full-length protein was confirmed by functional analysis of 
mutant CD14 molecules. The analysis of the structure-activity relationships of this 
peptide led to the rational design of LPS-neutralizing molecules with improved 
activity. 
2.3 Results 
2.3.1 Screening of overlapping 20-peptides for inhibition of LPS-induced IL-8 
production in THP-1 cells. 
To identify functional domains of human CD14 that interfere with LPS-induced 
signaling the entire mature 356-amino acid protein was covered by 35 synthetic 
20-peptides with 10 amino acids overlap (Table 2.1).  
All peptides were synthesized as fluorescein-labeled peptide amides by parallel 
solid-phase peptide synthesis using Fmoc-chemistry. N-terminal coupling of 
carboxyfluorescein was performed using optimized procedures for the labeling of 
peptide collections with uniform yields [176]. Labeling with carboxyfluorescein (i) 
allowed the reliable determination of peptide concentrations based on the 
absorption of the fluorophore and (ii) enabled the detection of potential interactions 
with living cells using fluorescence microscopy and flow cytometry.  
Except for the peptide corresponding to amino acids 21 to 40 all peptides were 
obtained in purities exceeding 75% as determined by RP-HPLC. Peptides were 
used for biological testing without further purification. For some hydrophobic 
peptides precipitates formed upon dilution of DMSO stock solutions into aqueous 
buffers. This problem was circumvented by first diluting the DMSO stock solutions 
1:10 in tert.-butyl alcohol/H2O (4:1) followed by dilution in aqueous buffers to the 
working concentrations. 
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Table 2.1 To cover the entire sequence of mature human CD14 fluorescein-labeled peptide 
amides of 20 amino acids with 10 amino acids overlap were synthesized. Except for peptide 
corresponding to amino acids 21-40 all peptides were obtained in purities exceeding 75%. Peptide 
amides were tested for their capacity to interfere with the LPS-induced IL-8 secretion.  
Sequence 
position 
Peptide sequence 
1-20 Fluo-TTPEPCELDDEDFRCVCNFS-NH2
11-30 Fluo-EDFRCVCNFSEPQPDWSEAF-NH2
21-40 Fluo-EPQPDWSEAFQCVSAVEVEI-NH2
31-50 Fluo-QCVSAVEVEIHAGGLNLEPF-NH2
41-60 Fluo-HAGGLNLEPFLKRVDADADP-NH2
51-70 Fluo-LKRVDADADPRQYADTVKAL-NH2
61-80 Fluo-RQYADTVKALRVRRLTVGAA-NH2
71-90 Fluo-RVRRLTVGAAQVPAQLLVGA-NH2
81-100 Fluo-QVPAQLLVGALRVLAYSRLK-NH2
91-110 Fluo-LRVLAYSRLKELTLEDLKIT-NH2
101-120 Fluo-ELTLEDLKITGTMPPLPLEA-NH2
111-130 Fluo-GTMPPLPLEATGLALSSLRL-NH2
121-140 Fluo-TGLALSSLRLRNVSWATGRS-HN2
131-150 Fluo-RNVSWATGRSWLAELQQWLK-NH2
141-160 Fluo-WLAELQQWLKPGLKVLSIAQ-NH2
151-170 Fluo-PGLKVLSIAQAHSPAFSCEQ-NH2 
161-180 Fluo-AHSPAFSCEQVRAFPALTSL-NH2
171-190 Fluo-VRAFPALTSLDLSDNPGLGE-NH2
181-200 Fluo-DLSDNPGLGERGLMAALCPH-NH2
191-210 Fluo-RGLMAALCPHKFPAIQNLAL-NH2
201-220 Fluo-KFPAIQNLALRNTGMETPTG-NH2
211-230 Fluo-RNTGMETPTGVCAALAAAGV-NH2
221-240 Fluo-VCAALAAAGVQPHSLDLSHN-NH2
231-250 Fluo-QPHSLDLSHNSLRATVNPSA-NH2
241-260 Fluo-SLRATVNPSAPRCMWSSALN-NH2
251-270 Fluo-PRCMWSSALNSLNLSFAGLE-NH2
261-280 Fluo-SLNLSFAGLEQVPKGLPAKL-NH2
271-290 Fluo-QVPKGLPAKLRVLDLSCNRL-NH2
281-300 Fluo-RVLDLSCNRLNRAPQPDELP-NH2
291-310 Fluo-NRAPQPDELPEVDNLTLDGN-NH2
301-320 Fluo-EVDNLTLDGNPFLVPGTALP-NH2
311-330 Fluo-PFLVPGTALPHEGSMNSGVV-NH2
321-340 Fluo-HEGSMNSGVVPACARSTLSV-NH2
331-350 Fluo-PACARSTLSVGVSGTLVLLQ-NH2
337-356 Fluo-TLSVGVSGTLVLLQGARGFA-NH2
 
Peptides were tested for their ability to interfere with LPS-induced IL-8 secretion 
in human monocyte-derived THP-1 myelomonocytic leukaemia cells. At a 
concentration of 10 µM one peptide, corresponding to amino acids 81 to 100 of 
human CD14, reduced the secretion of IL-8 by 80%. All other peptides exhibited 
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no significant inhibitory capacity (Figure 2.2). The peptide CD14 (21-40) was not 
obtained in adequate purity.  
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Figure 2.2 Influence of 20-peptide amides derived from human CD14 on the LPS-induced IL-8 
secretion in THP-1 cells. After 10 min incubation with fluorescein-labeled peptide amides (10 µM), 
THP-1 cells were treated with LPS (E. coli O111:B4, 20 ng/ml) for 5 h. The secretion of IL-8 was 
detected in cell free supernatants by ELISA. The LPS-induced IL-8 secretion is shown in relation to 
a sample that was incubated with buffer containing a concentration of DMSO/tert.-butyl alcohol 
corresponding to the one of the peptide-containing samples and stimulated with LPS. The 
individual 20-peptide amides are specified by their amino acid positions. In several synthetic 
approaches peptide CD14 (21-40) was not obtained in adequate purity (>75%). The error bars 
represent the standard deviation of triplicates within one experiment. 
 
For a fine mapping of the active region of the peptide CD14 (81-100) a further 
set of nine 20-peptides covering amino acids 73 to 108 with 18 amino acids 
overlap was synthesized and tested (Table 2.2). This second scan again 
confirmed CD14 (81-100) with the natural sequence as the most active peptide 
(Figure 2.3).  
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Table 2.2 For fine mapping of region 73 to 108 of mature human CD14 fluorescein-labeled 
peptide amides of 20 amino acids with 18 amino acids overlap were synthesized. Peptides were 
tested for their capacity to influence the LPS-induced IL-8 secretion. 
Peptide Sequence 
73-92 Fluo-RRLTVGAAQVPAQLLVGALR-NH2 
75-94 Fluo-LTVGAAQVPAQLLVGALRVL-NH2 
77-96 Fluo-VGAAQVPAQLLVGALRVLAY-NH2 
79-98 Fluo-AAQVPAQLLVGALRVLAYSR-NH2 
81-100 Fluo-QVPAQLLVGALRVLAYSRLK-NH2 
83-102 Fluo-PAQLLVGALRVLAYSRLKEL-NH2 
85-104 Fluo-QLLVGALRVLAYSRLKELTL-NH2 
87-106 Fluo-LVGALRVLAYSRLKELTLED-NH2 
89-108 Fluo-GALRVLAYSRLKELTLEDLK-NH2 
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Figure 2.3 Fine mapping of the region covering amino acids 73 to 108 of human CD14. After 
incubation (10 min) with fluorescein-labeled peptide amides (10 µM) cells were stimulated with LPS 
(20 ng/ml) for 5 h. Cell free supernatants were collected and analysed for IL-8 secretion by ELISA. 
The LPS-induced IL-8 secretion is shown in relation to a sample only stimulated with LPS. The 
individual 20-peptides are specified by their amino acid positions. Error bars represent the standard 
deviation of triplicates. 
 
The inhibitory effect of CD14 (81-100) was concentration-dependent (Figure 
2.4). Viability of cells was fully preserved for all peptides as determined by MTT-
assay (data not shown). At concentrations above 15 µM cytotoxicity of peptide 
CD14 (81-100) was observed.  
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Figure 2.4 Concentration dependence of the LPS-neutralizing activity of CD14 (81-100). After 
10 min incubation with the fluorescein-labeled peptide amide at the indicated concentrations, cells 
were stimulated with LPS (20 ng/ml) for 5 h. The LPS-induced IL-8 secretion is shown in relation to 
a sample stimulated with LPS in the absence of peptide. Error bars represent the standard 
deviation of triplicates. 
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2.3.2 Identification of residues in CD14 (81-100) critical for the inhibition of IL-8 
secretion. 
Residues important for the inhibitory capacity of CD14 (81-100) were identified 
by performing an alanine scan through the entire 20-amino acid sequence (Table 
2.3).  
 
Table 2.3 Fluorescent peptide amides with alanine substitutions for each amino acid position. 
Substituted 
amino acid 
Sequence 
Q Fluo-AVPAQLLVGALRVLAYSRLK-NH2
V Fluo-QAPAQLLVGALRVLAYSRLK-NH2
P Fluo-QVAAQLLVGALRVLAYSRLK-NH2
A Fluo-QVPAQLLVGALRVLAYSRLK-NH2
Q Fluo-QVPAALLVGALRVLAYSRLK-NH2
L Fluo-QVPAQALVGALRVLAYSRLK-NH2
L Fluo-QVPAQLAVGALRVLAYSRLK-NH2
V Fluo-QVPAQLLAGALRVLAYSRLK-NH2
G Fluo-QVPAQLLVAALRVLAYSRLK-NH2
A Fluo-QVPAQLLVGALRVLAYSRLK-NH2
L Fluo-QVPAQLLVGAARVLAYSRLK-NH2
R Fluo-QVPAQLLVGALAVLAYSRLK-NH2
V Fluo-QVPAQLLVGALRALAYSRLK-NH2
L Fluo-QVPAQLLVGALRVAAYSRLK-NH2
A Fluo-QVPAQLLVGALRVLAYSRLK-NH2
Y Fluo-QVPAQLLVGALRVLAASRLK-NH2
S Fluo-QVPAQLLVGALRVLAYARLK-NH2
R Fluo-QVPAQLLVGALRVLAYSALK-NH2
L Fluo-QVPAQLLVGALRVLAYSRAK-NH2
K Fluo-QVPAQLLVGALRVLAYSRLA-NH2
 
When leucines at positions 11 and 14, corresponding to positions 91 and 94 of 
mature CD14, were replaced by alanine the ability of the peptide to inhibit the 
LPS-induced IL-8 secretion was almost or fully lost. For peptides mutated at amino 
acids in positions 6, 7, 9, 12, and 16-20 the LPS-induced IL-8 secretion was 50 to 
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70%. In contrast, exchange of amino acids 1-3, 5, 8 and 13 by alanine did not 
affect the ability to inhibit the LPS-induced IL-8 secretion on THP-1 cells (Figure 
2.5). 
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Figure 2.5 Alanine scan for the identification of residues critical for CD14 (81-100) activity. 
Fluorescent peptide amides with positional alanine substitutions were screened for their ability to 
suppress the IL-8 production of LPS-stimulated THP-1 cells. Incubation conditions were identical to 
those described for Figure 2.2. Error bars represent the standard deviation of triplicates. 
2.3.3 Inhibitory activity of the murine homolog of CD14 (81-100) and the 
conservation of the sequence in CD14 proteins of different species. 
To address, whether the activity of the human CD14-derived peptide 
represented a functionally conserved property of the protein and not just an activity 
of this particular peptide, the corresponding fluorescein labeled peptide amide 
Fluo-RIPSRILFGALRVLGISGLQ-NH2 from murine CD14 was synthesized (Table 
2.4) and tested for its capacity to inhibit the LPS-induced IL-8 secretion in human 
THP-1 cells. The inhibitory activity of the murine peptide was comparable to the 
one of the human counterpart (Figure 2.6). The human and murine peptides have 
a high sequence similarity with identical amino acid residues in positions 3, 7, 9 to 
14, 17 and 19 and conservative exchanges in positions 2, 6 and 15.  
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Figure 2.6 Titration of THP-1 cells with mCD14 (96-115). THP-1 cells were incubated with the 
fluorescein-labeled peptide amide at the indicated concentrations for 10 min. Subsequently cells 
were stimulated with LPS (20 ng/ml) for 5 h and the LPS-induced IL-8 secretion was determined in 
cell free supernatants by ELISA. IL-8 secretion is shown in relation to a sample stimulated with LPS 
in the absence of peptide. Error bars represent the standard deviation of triplicates. 
 
A further sequence comparison of the human CD14 (81-100) peptide with the 
corresponding sequences of the murine, bovine, rat and rabbit proteins revealed a 
strict conservation of leucines 11 and 14, both of which were shown to be 
essential for the inhibitory activity of the human peptide. In addition, leucines in 
positions 7 and 19 were also fully conserved and in positions 2 and 6 only 
residues with aliphatic side chains were present (Table 2.4). 
 
Table 2.4 Sequence comparison amino acids 81-100 of human CD14 with the corresponding 
sequences of CD14 proteins from other species. Leucine residues in position 11 and 14 are bold-
face.  
Species Amino 
acids1 
Sequence 
human 100-119 QVPAQLLVGALRVLAYSRLK
bovine 99-118 QVPAQLLVAVLRALGYSRLK
rabbit 100-119 QVPAPLLLGVLRVLGYSRLK
mouse 96-115 RIPSRILFGALRVLGISGLQ
rat 101-120 RVPTQILFGTLRVLGYSGLR
 
1 The amino acid positions of the sequences refer to the ones of the immature proteins 
containing the putative signal peptides. 
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2.3.4 Binding of CD14 (81-100) to LPS aggregates 
Previous studies have shown that the domain comprising the amino acid 
residues 91-100 in human CD14 was involved in LPS-signaling rather than LPS-
binding [160]. Therefore we first assumed that CD14 (81-100) might interact with 
proteins involved in TLR4-dependent signaling, probably downstream of CD14. To 
determine whether the peptide interact with cells a fluorescein-labeled analogue of 
CD14 (81-100) was incubated with signaling competent THP-1 cells and analysed 
by confocal laser scanning microscopy and flow cytometry. However, up to a 
peptide concentration of 10 µM no binding of the peptide to the cells could be 
detected. Next, THP-1 cells were co-incubated with an analogue of CD14 (81-100) 
that was N-terminally labeled with the Cy5-like dye S0387 [177] and FITC-LPS. 
Again, the CD14 derived peptide did not bind to the cells but colocalized with 
aggregates of the TLR4-agonist probably resulting from a direct interaction 
between the two molecules (Figure 2.7).  
10 µm
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Figure 2.7 Co-incubation of THP-1 cells with a S0387-labeled peptide amide corresponding to 
the sequence 81-100 of human CD14 (10 µM) and FITC-LPS (1 µg/ml). After 30 min incubation 
cells were washed twice with medium and samples were imaged by confocal laser scanning 
microscopy: (A) FITC-LPS, (B) S0387-labeled peptide CD14 (81-100), merged (C), and 
transmission (D). The scale bar represents 20 µm. 
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2.3.5 Direct binding of bead-immobilized CD14 (81-100) to FITC-LPS 
Due to the fact that the inhibitory fluorescein-labeled peptides did not bind to 
cells, but directly interact with LPS aggregates, we more precisely investigated 
whether CD14 (81-100) exerted its inhibitory activity on IL-8 secretion by 
specifically binding to LPS. With a surplus in positive charge and a significant 
fraction of hydrophobic residues, CD14 (81-100) shares structural characteristics 
with other LPS-binding and -neutralizing peptides. Analogues of CD14 (81-100) N-
terminally elongated by two 8-amino-3,6-dioxaoctanoic acid spacer moieties and 
biotin were synthesized (Table 2.5) and bound to streptavidin-conjugated 
Sepharose beads.  
 
Table 2.5 Biotinylated peptide amides for immobilization on streptavidin-conjugated Sepharose 
beads to determine binding of FITC-LPS to CD14 (81-100). The peptides contain two 8-amino-3,6-
dioxaoctanoic acid spacers (Ado) between the biotin and the peptide moiety. 
Position Sequence 
81-100 Biotin-Ado-Ado-QVPAQLLVGALRVLAYSRLK-NH2 
171-190 Biotin-Ado-Ado-VRAFPALTSLDLSDNPGLGE-NH2 
 
The interaction of LPS with the peptide was investigated by incubation of a 
fluorescein-labeled LPS with beads loaded with CD14 (81-100) (Figure 2.8). 
Binding of FITC-LPS to the beads was specific for CD14 (81-100). For beads 
without peptide or loaded with the inactive peptide CD14 (171-190), bead-
associated fluorescence could be completely removed by washing the beads three 
times with PBS containing Tween (0.2%). The specificity of the binding was further 
confirmed by incubation of the CD14 (81-100)-loaded beads in the presence of 
FITC-LPS and either a 50-fold excess of unlabeled LPS or in the presence of a 
CD14 (81-100) analogue with improved solubility (peptide 31, see below).  
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Figure 2.8 LPS-binding by CD14 (81-100). Streptavidin beads loaded with biotinylated CD14 
(81-100) were incubated with (A) FITC-LPS (2 µg/ml), (B) co-incubation with FITC-LPS and 150 
µg/ml unlabeled LPS, co-incubation with (C) 20 µM or (D) 2 µM unlabeled peptide 31 (Table 2.7). 
The specificity of the LPS binding was further confirmed by incubation of peptide-free streptavidin 
beads with FITC-LPS and (E) by incubation of streptavidin beads loaded with biotinylated peptide 
CD14 (171-190) with FITC-LPS (F). Beads were analysed by fluorescence microscopy. The scale 
bar corresponds to 200 µm.  
2.3.6 Validation of the LPS-binding site in the full length protein 
In the recently published crystal structure of human CD14 [178] leucine residues 
at positions 87, 91 and 94 point inwards into the putative LPS-binding pocket 
(Figure 2.9). However, the crystal structure was obtained in the absence of ligand 
and therefore a functional role of these residues in the recognition of ligand still 
remains to be demonstrated. The alanine scan suggested that at least in the 
context of the CD14-derived peptide these residues are required for the inhibitory 
activity. 
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Figure 2.9. The crystal structure of CD14. Residues 81-100, comprising helix 4, are coloured in 
green and leucine residues 87, 91 and 94 are shown in red. Side chains of the leucine residues 
point into the N-terminal pocket which corresponds to the putative LPS binding site of the protein.  
 
 To validate this result in the context of the entire protein, mutant CD14 proteins, 
in which the relevant leucine residues were changed to either glutamine or proline 
residues, were expressed in HEK 293T cells and analysed for FITC-LPS binding 
by flow cytometry and confocal laser scanning microscopy (Figure 2.10). Cells 
expressing the wild type CD14 protein bound FITC-LPS efficiently, whereas cells 
expressing mutant CD14 proteins at comparable levels did not show any LPS-
binding capacity. Confocal laser scanning microscopy confirmed that cells 
expressing high levels of the mutant protein at the plasma membrane did not show 
any LPS binding. 
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Figure 2.10 Binding of LPS to HEK 293T cells expressing wild-type and mutated CD14. Wild 
type CD14 (A), CD14 [Leu 87, 91, 94 Gln] (B), and [Leu 87, 91, 94 Pro] (C) were expressed in HEK 
293T cells and binding of FITC-LPS was determined by flow cytometry and fluorescence 
microscopy. Cells expressing wild-type CD14 that were not incubated with FITC-LPS (D) and cells 
electroporated with the vector alone and incubated with FITC-LPS (E) served as negative controls. 
Electroporated cells were seeded at a density of 100,000/well in 96-well plates or 40,000 cells/well 
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in 8-well chambered cover glasses for analysis by flow cytometry or confocal laser scanning 
microscopy, respectively. Cells were incubated with FITC-LPS (1 µg/ml) for 1 h at 4°C. Then cells 
were incubated with a polyclonal sheep anti-human CD14 antibody (5 µg/ml) followed by incubation 
with a phycoerythrin-conjugated donkey anti-sheep antibody (1:100 dilution) for 1 h in each case. 
Shown are dot plots of phycoerythrin fluorescence versus fluorescein fluorescence of cells 
analysed by flow cytometry and confocal microscopy images. The scale bar represents 20 µm. 
2.3.7 Inhibitory activity of derivatives of CD14 (81-100) with higher solubility. 
LPS-binding peptides derived from LPS-binding proteins provide a valuable 
source of LPS-neutralizing agents with therapeutic potential. However, CD14 (81-
100) exhibited only poor solubility. For this reason analogues of CD14 (81-100) 
with improved solubility were designed using two different strategies: (i) C-terminal 
elongation of the peptide with a tetra-lysine or a penta-glutamic acid stretch and (ii) 
replacement of uncharged amino acids within the peptide by either lysine or 
glutamic acid residues. The results of the alanine scan suggested that amino acids 
at positions 5, 9, 13, and 17 could be exchanged with minimum loss of biological 
activity. A total of four internally substituted analogues with either lysine or 
glutamic acid in all four positions or alternating substitutions of lysine/glutamic acid 
or glutamic acid/lysine were synthesized (Table 2.6).  
 
Table 2.6 CD14 (81-100) analogues with increased solubility. In the fluorescein-labeled peptide 
amides 23 and 24 leucine residues at positions 11 and 14 were replaced by alanine in order to 
confirm the significance of these residues for the LPS-neutralizing activity. 
Peptide Sequence 
Peptide   1 Fluo-QVPAQLLVGALRVLAYSRLK-NH2 
Peptide 11 Fluo-QVPAKLLVKALRKLAYKRLK-NH2 
Peptide 12 Fluo-QVPAKLLVEALRKLAYERLK-NH2 
Peptide 13 Fluo-QVPAELLVKALRELAYKRLE-NH2 
Peptide 14 Fluo-QVPAELLVEALRELAYERLE-NH2 
Peptide 21 Fluo-QVPAQLLVGALRVLAYSRLKKKKK-NH2 
Peptide 22 Fluo-QVPAQLLVGALRVLAYSRLKEEEEE-NH2 
Peptide 23 Fluo-QVPAQLLVGAARVLAYSRLKKKKK-NH2 
Peptide 24 Fluo-QVPAQLLVGALRVAAYSRLKKKKK-NH2 
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The substitutions markedly increased the solubility of all peptides so that 
concentrations of up to 50 µM in aqueous buffers could be tested.  
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Figure 2.11 LPS-neutralizing activity of CD14 (81-100) analogues with increased solubility. The 
peptides were tested for their ability to suppress LPS-induced IL-8 secretion in THP-1 cells (A-B) 
and LPS-induced TNF-α secretion in THP-1 cells differentiated with PMA (C-D). After incubation 
with varying concentrations of fluorescent peptide amides (10 min) cells were stimulated with LPS 
(20 ng/ml) for 5 h. The higher toxicity of the analogues with substitutions within the peptide 
(peptides 11, 12, 13, 14) precluded a testing of concentrations above 1 µM. The symbols 
correspond to the following fluorescent peptide amides (Table 2.6): peptide 11: ○; peptide 12: ◊; 
peptide 13: □; peptide 14: ∆; peptide 21: ▲; peptide 22: x; peptide 23: ♦; peptide 24: ■. Error bars 
represent the standard deviation of triplicates.  
However, only for the peptide in which all residues were substituted for lysine 
(peptide 11) and for the peptide with the C-terminal tetra-lysine (peptide 21) the 
capacity to inhibit IL-8 secretion was preserved or even improved (Figure 
2.11A,B). For the latter an IC50 value of about 500 nM and a maximum inhibition of 
80% at a concentration of 1 µM were determined. For peptide 11 with the internal 
lysine substitutions, the IL-8 secretion was inhibited by 50% at a concentration of 1 
µM. In agreement with the results of the alanine scan lysine-elongated analogues 
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containing alanine substitutions of leucines in position 11 and 14 (peptides 23 and 
24) exhibited a significant decrease in inhibitory activity in the applied 
concentration range.  
Concerning the significance of TNF-α in the clinical progress of septic shock 
[179;180], the analogues with higher solubility were tested for their capacity to 
inhibit the secretion of this cytokine (Figure 2.11C,D). In order to render the THP-1 
cells competent for the LPS-dependent secretion of TNF-α the cells were 
incubated with PMA for 72 h prior to stimulation with LPS. Peptides 11 and 21 
inhibited the LPS-induced TNF-α secretion in a dose-dependent manner. In 
accordance with the results obtained for the inhibition of IL-8 induction, the 
introduction of negative charges within the peptide or at the C-terminus abolished 
the inhibitory activity. Substitution of leucines in positions 11 (peptide 23) and 14 
(peptide 24) reduced but did not fully abolish the inhibitory activity of the peptides. 
Several peptides exhibited cytotoxic effects against THP-1 cells detected as a 
reduction in the absorbance measured in the MTT test. Peptide CD14 (81-100) 
was cytotoxic at concentrations above 15 µM. Peptides 11 and 21 displayed 
cytotoxicity at concentrations higher than 1 µM and 5 µM, respectively. In contrast, 
peptides 12, 13, 14, 22, 23 and 24 that exhibited no or reduced inhibitory activity 
also showed no cytotoxic effect against THP-1 cells even at higher concentrations. 
Cytotoxicity in the lower to mean micromolar range is a general observation for 
cationic LPS-binding and antimicrobial peptides [181]. 
2.3.8 Confirmation of the LPS neutralizing activity by the Limulus amebocyte 
lysate assay 
To validate the LPS-neutralizing capacity of the CD14-derived peptides by a 
further well established assay, the chromogenic Limulus amebocyte lysate (LAL) 
assay was performed (Figure 2.12). Initial experiments had shown that peptide 
concentrations in the lower to mean micromolar range were required to determine 
the activity in the LAL test. For this reason, this analysis was restricted to the 
analogues with higher solubility containing lysine substitutions at position 5, 9, 13 
and 17. To exclude a disturbance of the read-out of the LAL test by the fluorescein 
moiety, for this study all peptides were N-terminally acetylated instead of 
fluorescein-labeled (Table 2.7).  
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Table 2.7 Acetylated 20-peptide amide analogues of CD14 (81-100) used for the analysis of the 
structure-activity relationships. 
Peptide Sequence 
Peptide 30 Ac-QVPAQLLVGALRVLAYSRLK-NH2 
Peptide 31 Ac-QVPAKLLVKALRKLAYKRLK-NH2 
Peptide 32 Ac-QVPAKLLVKAARKLAYKRLK-NH2 
Peptide 33 Ac-QVPAKLLVKAARKAAYKRLK-NH2 
Peptide 34 Ac-QVPAKLLVKAQRKLAYKRLK-NH2 
Peptide 35 Ac-QVPAKLLVPALRKLAYKRLK-NH2 
Peptide 36 Ac-QVAAKLLVKALRKLAYKRLK-NH2 
Peptide 37 Ac-QVPAQLLVGAARVLAYSRLK-NH2 
Peptide 38 Ac-KVPAKLLVKALRKLAYKRLK-NH2 
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Figure 2.12 Inhibition of the endotoxin-induced LAL reaction by acetylated peptide amide 
analogues of CD14 (81-100). Increasing concentrations of peptide amides were incubated with 
LPS (1 endotoxin unit) for 45 min and subsequently the LAL reaction was performed as described 
under experimental procedures. Absorbance was quantitated at a wavelength of 405 nm. Symbols 
correspond to the following acetylated peptide amides (Table 2.7): peptide 31: ♦; peptide 32: ■; 
peptide 33: ▲; peptide 34: ●; peptide 35: ; peptide 36: x. 
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In contrast to the native sequence, for the analogue with the internal lysine 
substitutions (peptide 31) the substitution of a relevant leucine residue in position 
11 by alanine (peptide 32) did not decrease the inhibitory activity. However, when 
both relevant leucine residues in position 11 and 14 were exchanged (peptide 33), 
a decrease in activity by 50% was observed. Both, the exchange of the leucine 
residue at position 11 by a glutamine residue (peptide 34), and the exchange of a 
lysine residue by proline in position 9 (peptide 35) led to a complete loss of activity 
in the tested concentration range of up to 50 µM. In contrast, substitution of the 
naturally occurring proline at position 3 by an alanine residue (peptide 36) 
increased the activity more than two-fold, yielding an IC50 of about 10 µM (Figure 
2.12). 
The LAL assay was applied to determine the ability of the CD14-derived 
peptides to neutralize LPS other than E. coli serotype O111:B4. These include 
LPS from Pseudomonas aeroginosa, Klebsiella pneumoniae, Salmonella 
friedenau, Salmonella typhimurium and Rd-LPS from E. coli (Figure 2.13).  
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Figure 2.13 Inhibition of the LAL reaction induced by several endotoxins by a CD14-derived 
peptide amide. Peptide 31 (50 µM) was incubated with LPS (2 endotoxin units) for 45 min prior 
performing the LAL reaction as described under experimental procedures. Error bars represent 
mean deviations of triplicates. 
 
The derivative with enhanced solubility (peptide 31) was able to almost 
completely block both types of LPS from Salmonella at a concentration of 50 µM. 
The inhibitory activity was even stronger than that against O111:B4 LPS from E. 
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coli. LPS from Pseudomonas aeroginosa and Klebsiella pneumoniae were 
inhibited by about 50%. Interestingly, in contrast to the smooth type LPS, peptide 
34 was not able to neutralize Rd-LPS from the rough mutant from E. coli, which 
lacks the O-antigen, at the tested concentrations. 
Next, it was tested whether the peptide corresponding to the native sequence 
was able to inhibit the IL-8 induction induced by LPS molecules other than E. coli 
serotype O111:B4. Only LPS from Pseudomonas aeroginosa and Salmonella 
typhimurium induced an IL-8 and TNF-α response in THP-1 cells and therefore 
only these two LPS could be applied for these inhibition experiments. For both 
LPS molecules a concentration-dependent inhibition of the IL-8 secretion was 
observed (Figure 2.14). In accordance to the results obtained from the LAL assay 
the inhibitory activity of CD14 (81-100) against LPS from S. typhimurium was 
stronger than that against E. coli and P. aeroginosa LPS. 
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Figure 2.14 Inhibition of the IL-8 secretion induced by several endotoxins by peptide amide 
CD14 (81-100). Peptide CD14 (81-100) was incubated at the indicated concentrations with THP-1 
cells for 10 min and subsequently cells were stimulated with LPS (100 ng/ml) for 5 h. IL-8 secretion 
was determined in the supernatant of the cells by ELISA. Error bars represent mean deviations of 
triplicates. 
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2.3.9 Determination of peptide conformation by CD spectroscopy. 
In the crystal structure of CD14, amino acids 81 to 100 comprise an α-helix 
segment (amino acids 82-94) that is followed by a sharp bend of residues present 
in an elongated conformation (Figure 2.9). Only in an α-helical conformation the 
three leucine side chains required for the LPS-neutralizing activity of the peptide 
are placed on one face of the α-helix. Circular dichroism measurements allowed 
an estimation of the α-helix content for the peptides (Figure 2.15).  
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Figure 2.15 Secondary structures of CD14-derived peptides determined by CD-spectroscopy. 
Far UV-CD spectra for three CD14-derived acetylated peptide amides are shown as mean residue 
molar ellipticity versus wavelength (nm). The spectra were recorded at a peptide concentration of 
10 µM at room temperature (A) in 10 mM sodium phosphate buffer, pH 7.4 without or (B) in 10 mM 
sodium phosphate buffer to which TFE was added to 20% (v/v). 
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 In phosphate buffer the peptides 30, 31 and 37 (Table 2.7) had little secondary 
structure, as evidenced by a negative ellipticity at 200 nm (Figure 2.15A). As 
shown in Figure 2.15B the CD spectra of the individual peptides in the presence of 
20% (v/v) TFE, an organic solvent that is often used as a membrane mimetic to 
lower the polarity, were almost indistinguishable from each other. The α-helix 
content increased in the presence of TFE from 31 to 52, 33 to 64 and 31 to 62% 
for peptides 30, 31 and 37, respectively (Figure 2.16). The reduced hydrophobicity 
and enhanced amphipathicity of peptide 31 slightly enhanced the helix content 
compared to the native sequence. These results indicate that the lower activity of 
the peptides with the leucine to alanine exchanges were not due to structural 
effects but rather to a loss of molecular contacts required for tight binding to LPS.  
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Figure 2.16 Secondary structure content of peptides 30, 37 and 31 determined by CDfit. The 
spectra were recorded in 10 mM sodium phosphate buffer, pH 7.4 without (A) or in the presence of 
20% TFE (B) at a peptide concentration of 10 µM at room temperature. 
 
Based on the results from the CD-measurements the positions of the residues 
forming an α-helix are illustrated in a helical-wheel projection (Figure 2.17).  
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Figure 2.17 Schiffer Edmundson wheel projections of CD14-derived peptide amides. The helical 
wheel describes the order and position of amino acids along the axis of the α-helix. (A) Peptide 
corresponding to amino acids 83 to 100 of human CD14 and (B) peptide analogue containing 
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internal lysine substitutions. (C-F) Residues are schematically represented by bars with lengths 
that reflect the side-chain size and coloured white for highly hydrophilic, grey for moderate 
hydrophilic and black for hydrophobic characteristics. Shown are (C) the native sequence, (D,E) 
the alanine substitution mutants that failed to inhibit the LPS-induced cytokine secretion and (D) the 
derivative containing internal lysine substitutions.  
In this conformation the relevant hydrophobic leucine residues are located at 
one side along the axis of the helix forming a hydrophobic face. This part might be 
involved in the binding of a hydrophobic domain of the LPS ligand. The derivative 
containing additional lysine residues (Figure 2.17B) exhibits an amphipathic 
structure with an opposite hydrophilic and a hydrophobic face of the helix. 
Analogues of CD14 (81-100) in which the relevant leucine residues are substituted 
by alanine residues exhibited strongly reduced inhibitory activity. This indicates 
that not only the hydrophobic character of the amino acid but also the length of the 
side chain might be responsible for the inhibitory activity of the peptide. 
2.3.10 Inhibition of the cellular binding of FITC-LPS by CD14-derived peptides. 
To further define the inhibitory mode of action of the CD14-derived peptides we 
determined whether these peptides prevented LPS from binding to cells or 
whether the LPS-peptide complexes could still bind but failed to activate the 
receptor. For this purpose, CD14-expressing CHO cells were incubated with FITC-
conjugated LPS in the presence or absence of CD14-derived peptides and the 
cell-associated fluorescence was determined by flow cytometry (Figure 2.18). 
Peptide amides 30, 31 and 36 suppressed the binding of FITC-LPS by 70 to 80% 
at concentrations of 16, 6.5 and 2.5 µM, respectively. Peptides with enhanced 
amphipathicity (peptide 31 and 36) were more efficient in inhibiting the binding of 
FITC-LPS than the peptide corresponding to the native sequence of CD14 (81-
100) (peptide 30). The highest activity was again observed for the peptide in which 
the proline residue at position 3 was exchanged by an alanine residue (peptide 
36). In contrast, at a concentration of 2.5 µM peptide amides 34 (Leu11 to Gln) 
and 35 (Lys9 to Pro) had no inhibitory effect. 
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Figure 2.18 Effect of CD14-derived peptides on the binding of FITC-conjugated LPS to CHO 
cells. Cells were incubated with FITC-conjugated LPS (400 ng/ml) in the presence of peptide 30 
(15 µM), peptide 31 (6.5 µM), peptide 36, peptide 34, peptide 35 (2.5 µM) for 3 h at 37°C. After 
washing the cells twice with medium, trypsinization and washing once with PBS, cellular 
fluorescence was determined by flow cytometry. Columns represent median fluorescence of vital 
cells relative to cells treated with FITC-LPS, only. Error bars represent the mean deviation of 
duplicates. 
 
2.3.11 Antimicrobial activity of CD14-derived peptides. 
Due to their homology to various α-helical antimicrobial peptides (see 
introduction) the antimicrobial activities of the CD14-derived peptides were 
investigated. For this purpose E. coli bacteria were grown in the presence or 
absence of peptide amides 31 and 38 (Table 2.7). Both peptide amides totally 
suppressed bacterial growth down to a concentration of 1.25 µM (peptide 31) and 
0.6 µM (peptide 38) (Figure 2.19). The peptide 38 is an analogue containing a 
glutamine to lysine substitution in position 1 in order to enhance positive charge 
and amphipathicity. The enhanced amphipathicity of the peptide might be 
responsible for its enhanced antimicrobial activity compared to peptide 31. 
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Figure 2.19 Impact of CD14-derived peptides on the growth of E. coli. Acetylated peptide 
amides were diluted in RPMI/10% FBS to the indicated concentrations. 10 µl of a suspension of the 
bacteria were then added to 200 µl of the corresponding peptide solution and incubated for 16 h at 
37°C. The DMSO control contains 0.1% DMSO according to the amount of DMSO in the vial 
containing peptide at a concentration of 10 µM. Wells without bacteria appear dark, wells with 
bacteria bright.  
 
2.4 Discussion 
2.4.1 LPS-binding domain of CD14 
Mapping of the full length human CD14 protein with synthetic 20-peptide amides 
which overlapped by 10 amino acids identified a single peptide amide with LPS-
neutralizing activity corresponding to amino acids 81-100 of the mature protein. 
Using peptide-functionalized Sepharose beads it was shown that this peptide 
binds FITC-LPS from E. coli serotype O111:B4.  
Recently a crystal structure of CD14, obtained in the absence of ligand, was 
published [178]. Amino acids 82-94 comprise an α-helix with one face oriented 
towards an intramolecular pocket and the other face directed outwards. The 
analysis of the structure-activity relationships of the peptide revealed that leucine 
residues corresponding to residues 87, 91 and 94 are required for biological 
activity. These residues are all located on the face of the helix that is directed into 
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the interior of the protein. The physiological significance of these residues for 
binding of LPS was confirmed by the failure of mutant proteins in which these 
residues were exchanged to either glutamine or proline residues to bind LPS. Our 
peptide mapping approach therefore provides strong evidence that the LPS-
binding domain of CD14 is located in the interior of the protein and identifies 
residues directly involved in binding of LPS (Figure 2.9).  
A hydrophobic binding pocket is able to shield hydrophobic determinants of an 
amphipatic molecule against the polar environment. Two proteins involved in 
binding and transport of hydrophobic molecules contain such a binding pocket. 
BPI complexes phosphatidylcholine within an apolar pocket formed by two 
amphipathic α-helices and two β-sheets [182]. Hydrophobic residues of an α-helix 
of this binding pocket are directly involved in the binding of the apolar acyl-chains 
of the phosphatidylcholine ligand (Figure 2.20).  
 
A B
C D
 
 
Figure 2.20 Crystal structure of BPI in complex with two phosphatidylcholine molecules (grey). 
Acyl chains of phosphatidylcholine are bound to hydrophobic amino acids (green) of an α-helix 
(blue) within BPI. Figures were created by Rasmol. 
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The bacterial lipopeptide localization factor LolA also contain a ligand binding 
pocket formed by a β-barrel in which lipoproteins are bound and transported 
across the membrane of the bacteria [183]. 
Several studies have focused on the identification of LPS-binding and -signal 
transducing domains of human CD14. The failure to detect the LPS-binding 
activity of amino acids 81 to 100, previously, may be due to the different strategies 
applied for the identification of the binding sites. For an LPS-binding domain 
formed by several separate binding sites, limited mutation of only one site may 
only slightly affect the affinity of the entire protein. However, based on our analysis 
of the structure-activity relationships for the peptide we were able to identify the 
amino acids involved in LPS binding and confirm their relevance for the full length 
protein by simultaneous site-specific mutation for amino acids with different 
physicochemical properties or conformational characteristics. 
The reason why CD14 (81-100) was the only peptide exhibiting an LPS-
neutralizing activity in our assays may be based on the fact that among those 
peptides corresponding to parts of the LPS-binding domain, this peptide may be 
the only one assuming a conformation similar to the one of the corresponding 
region in the native protein. CD spectroscopy confirmed that under relatively mild 
helix-inducing conditions CD14 (81-100) derived peptides possessed a 
considerable α-helix content, consistent with the secondary structure of this 
domain in the crystal structure. 
Given the previous observation that mutations of residues 91 to 101 affected the 
signal transducing capacity we hypothesized that CD14 (81-100) might also have 
the ability to mimic the functional domain of CD14 responsible for binding to 
cellular receptors. However, when the fluorescein-labeled analogue of the peptide 
was incubated with signaling-competent THP-1 cells no binding could be detected. 
The CD14 derived peptide with enhanced solubility (peptide 31) neutralized 
smooth LPS from different bacterial strains in the LAL assay but failed to inhibit the 
LAL reaction induced by rough LPS. This activity profile for the peptide is 
consistent with a recent report that CD14 does not only enhance the 
responsiveness of cells to LPS but also contributes to the discrimination of 
different types of LPS [184]. Removal of increasing amounts of carbohydrate 
decreased the activity and this residual activity was increasingly CD14-
independent. Amino acids 81-100 might therefore interact with carbohydrates of 
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the O-antigen rather than the lipid A moiety of LPS and thereby contribute to the 
ligand specificity of CD14. In spite of the remarkable agreement of the activity 
profiles further experiments will be needed to determine, whether LPS is buried so 
deeply in the ligand-binding pocket. 
Our data indicate that the CD14-derived peptides neutralize the cell stimulating 
and -binding properties of LPS by complex formation. We did not determine 
directly, to which degree the binding of LPS with LPS-binding molecules involved 
in the activation of TLR4 was inhibited or whether the peptide interfered with the 
activity once LPS was bound to one of these molecules. Effective molecular 
recognition of endotoxin requires the concerted action of several extracellular and 
cell surface proteins in addition to TLR4 which bind and transfer LPS. In serum, 
LPS micelles form complexes with the lipid transfer protein LBP. LBP potently 
enhances the agonistic activity of LPS [185;186] by accelerating the transfer of 
monomeric LPS molecules to CD14 [186-188]. CD14-bound endotoxin is then 
transferred to MD-2 and TLR4 [20;189]. Given this molecular mechanism it seems 
unlikely that LPS once bound to a cofactor is accessible to the LPS neutralizing 
peptides. In our experiments, we observed that the inhibitory activity of the CD14-
derived peptides was enhanced when the dilution of the LPS stock solution to 
working concentrations was performed under serum-free conditions. Serum 
constitutes a source for LBP and complex formation between LPS and LBP during 
dilution in a serum-containing buffer, might therefore limit the inhibitory activity of 
the peptides. It was previously shown that several structurally diverse LPS-
neutralizing cationic peptides inhibit the interaction of LPS with LBP [142]. Based 
on these and our observations we propose that our peptides might block the initial 
binding to LBP. However this has to be determined in future experiments. 
2.4.3 Comparison of CD14 (81-100) with LPS-binding peptides from other 
proteins 
Recent effords to develop molecules that neutralize endotoxin have 
concentrated on characterizing lipid A-binding regions from endotoxin-binding 
peptides and proteins. The crystal structure of LALF revealed a positively charged 
amphipathic loop with basic residues facing to one side that contributes to LPS-
binding [163]. Similar motifs were proposed for other endotoxin-binding proteins, 
namely BPI, LBP [163;164], heparin-binding protein [190] and lactoferrin [191]. 
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LPS-binding studies with synthetic peptides designed to mimic the putative LPS-
binding site of these proteins showed that a stabilization of a β-turn conformation 
by disulfide bridges or insertion of β-turn-inducing amino acids was required for 
high affinity endotoxin binding and neutralization [162;164;168;170;191-194].  
In addition to LPS-neutralizing molecules with β-sheet structure, some α-helical 
cationic peptides exhibit high LPS-binding and -neutralizing activity. These include 
antimicrobial peptides derived from silk moth cecropin and bee mellitin [127;129], 
human CAP18 [107;128], and guinea pig CAP11 [195].  
Our results obtained by the analysis of the structure-activity relationships and 
CD spectroscopy revealed that the CD14-derived LPS neutralizing peptides can 
be assigned to the class of α-helical peptides with antimicrobial activity. This was 
supported by the observation that the CD14-derived peptides inhibited bacterial 
growth down to a concentration of 1 µM (Figure 2.19). 
 The amino acid residues leucines 11 and 14 that are critical for biological 
activity are three residues apart. In addition, the lysine-substituted variant of the 
native sequence exhibits a pattern of aliphatic and cationic amino acid residues 
that is characteristic for cationic amphipathic α-helices. Similar properties have 
been reported for the LPS-binding and -neutralizing 18-amino acid peptide derived 
of the C-terminal part of CAP18 [128;171]. Further evidence for an α-helical 
conformation of CD14 (81-100) was obtained by removal or introduction of proline 
residues. Mutation of the proline residue to alanine in position 3 yielded a more 
potent peptide as shown by the significantly enhanced LPS-neutralizing activity in 
the LAL test. In contrast, the activity of the peptide was significantly reduced when 
lysine at position 9 was substituted by a proline residue.  
To this end it was not possible to determine to which degree the increase in 
activity was due to the enhanced solubility of the lysine-substituted peptides or due 
to additional molecular interactions of the positively charged amino acid side 
chains with the negatively charged groups of LPS. The observation that the C-
terminal elongation of the peptide increased the activity even stronger than the 
internal lysine substitutions indicates that the higher solubility was the major 
contribution to the higher activity.  
This is the first report of a peptide with LPS-neutralizing activity derived from 
CD14. While previous analyses on LPS-neutralizing peptide motifs have stressed 
the significance of cationic residues, for CD14 (81-100) side chains with 
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substantial hydrophobicity proved to be essential for activity. For the inactive 
derivatives containing leucine to alanine substitutions the smaller and less 
hydrophobic alanine side chain is not able to sustain the inhibitory activity of the 
peptide. These side chains likely engage in interactions with LPS that also play a 
role for LPS binding in the entire protein. Due to the ability to generate CD14 (81-
100) analogues with higher solubility we are confident that the CD14-derived 
peptide is a promising candidate for a further development of LPS-neutralizing 
peptides for use in the prevention and treatment of septic shock. 
2.5 Materials and methods 
2.5.1 Reagents 
Lipopolysaccharide (phenol extracted and purified by ion-exchange 
chromatography) and fluorescein isothiocyanate-labeled lipopolysaccharide (FITC-
LPS), both from E. coli serotype O111:B4, lipopolysaccharides from Pseudomonas 
aeroginosa, Klebsiella pneumoniae, Salmonella friedenau, Salmonella 
typhimurium and Rd-LPS from E. coli, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT), and phorbol 12-myristate 13-acetate (PMA) were from 
Sigma (Taufkirchen, Germany), Limulus amebocyte lysate was from BioWhittaker 
(Walkersville, USA). Standard chemicals were from Fluka (Deisenhofen, 
Germany) and Merck (Darmstadt, Germany). Fmoc-amino acids were from 
Novabiochem, Senn Chemicals (Dielsdorf, Switzerland), and Orpegen Pharma 
(Heidelberg, Germany). The isomeric mixture of 5(6)-carboxyfluorescein was from 
Fluka. G418 was from Gibco (Karlsruhe, Germany) and Hygromycin from PAN 
Biotech (Aidenbach, Germany). 
2.5.2 Peptide synthesis 
Parallel peptide amide synthesis [196] was performed by solid-phase Fmoc/tert.-
butyl chemistry using an automated peptide synthesizer for multiple peptide 
synthesis (Syro, MultiSynTech, Bochum, Germany). Peptide amides were 
synthesized on Rink amide resin (Rapp Polymere, Tübingen, Germany). Side 
chain-protecting groups of Fmoc-amino acids were tert.-butyl (Ser, Thr, Tyr, Glu, 
Asp), 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Arg), trityl (Asn, Gln, 
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Cys, His), tert.-butyloxycarbonyl (Trp, Lys). Fmoc-protected amino acids including 
Fmoc-8-amino-3,6-dioxaoctanoic acid (Fmoc-Ado-OH) (Neosystem, Strasbourg, 
France) were coupled by in situ activation using N,N’-diisopropylcarbodiimide/1-
hydroxybenzotriazol for 90 min in 2 ml syringes. The removal of the Fmoc-
protecting group was carried out by treatment with piperidine/DMF (1:4, v/v), twice 
for 8 min. The resin was washed with DMF (6x) after each coupling and 
deprotection step. Peptide amides were cleaved off the resin and side-chain-
deprotected by treatment with trifluoroacetic acid/triisopropylsilane/ethanedithiol/ 
H2O (92.5:2.5:2.5:2.5, v/v/v/v) for 4 h. Crude peptides were precipitated by adding 
cold diethyl ether (-20°C). The precipitated peptides were collected by 
centrifugation and resuspended in cold diethyl ether. This procedure was repeated 
twice. Finally peptides were dissolved in tert.-butyl alcohol/H2O (4:1, v/v) and 
lyophilized three times.  
2.5.3 Labeling of peptide amides with carboxyfluorescein 
N-terminal labeling of the peptide amides with 5(6)-carboxyfluorescein was 
performed as described [176]: Fmoc-deprotected, resin-bound peptides were 
reacted with 5 equiv. of 5(6)-carboxyfluorescein, N,N’-diisopropylcarbodiimide, and 
1-hydroxybenzotriazol each in DMF for 16 h. Reactions were stopped by washing 
the resins three times with DMF, methanol, dichloromethane and diethyl ether. 
Subsequently, peptides were treated with piperidine/DMF (1:4, v/v) for 20 min in 
order to remove ester-bound carboxyfluorescein. Completeness of labeling was 
confirmed by Kaiser-Test [197]. 
2.5.4 Labeling of peptide amides with S0387 
S0387 was covalently attached to the deprotected N-terminus using 5 equiv. of 
DIC (11.7 µl, 75 µmol), 5 equiv. of HOBt (11.5 mg, 75 µmol) and 1.5 equiv. of 
S0387 (15.9 mg, 22,5 µmol) in DMF twice for 16 h. Reactions were stopped by 
washing the resins three times with DMF, methanol, dichloromethane and diethyl 
ether. Completeness of labeling was confirmed by Kaiser-Test 
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2.5.5 Biotinylation of resin-bound peptide amides. 
Conjugation of biotin to the N-terminus of resin-bound peptides was performed 
using 5 equiv. biotin, 5 equiv. 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
tetrafluoroborate, 5 equiv. 1-hydroxybenzotriazol, and 10 equiv. N,N’-
diisopropylethylamine in N-methylpyrrolidone for 16 h. Completeness of 
biotinylation was confirmed by Kaiser-Test. 
2.5.6 Acetylation of resin-bound peptide amides 
Nα-Acetylation was performed in the presence of acetic anhydride, N,N’-
diisopropylethylamine, and DMF (1:1:8, v/v/v) for 2 x 30 min. Completeness of Nα-
acetylation was confirmed by Kaiser-Test. 
2.5.7 HPLC 
Peptides and conjugates were analyzed by analytical RP-HPLC. Gradient: 
water/0.1% TFA (solvent A) and acetonitrile/0.1% TFA (solvent B) (Waters 600 
System (Eschborn, Germany)), detection at 214 nm. The samples were analyzed 
on an analytical HPLC column (Nucleosil 100, 250 x 2 mm, C18 column, 5 µm 
particle diameter; Grom, Herrenberg, Germany), using a linear gradient from 10% 
B to 100% B within 30 min (flow rate: 0.3 ml/min). Peptides were purified by 
preparative RP-HPLC (Nucleosil 300, 250 x 20 mm, C18 column, 10 µm particle 
diameter; Grom, Herrenberg, Germany) on a Gilson preparative system (Bad 
Camberg, Germany, equipped with a 321 Pump and a 156 UV/Vis Detector, flow 
rate: 10 ml/min). Gradients were adjusted according to the elution profiles and 
peak profiles obtained from the analytical HPLC chromatograms. 
2.5.8 Mass spectrometry of synthetic peptides 
1 µl of 2,6-dihydroxyacetophenone matrix (20 mg of 2,6-dihydroxyacetophenone 
and 5 mg of ammonium citrate in 1 ml of isopropyl alcohol/H2O (4:1, v/v)) were 
mixed with 1 µl of each peptide solution (dissolved in acetonitrile/water (1:1, v/v) at 
a concentration of 1 mg/ml) on a gold target. Measurements were performed using 
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a matrix-assisted laser desorption ionization (MALDI) time-of-flight mass 
spectrometer (G2025A, Hewlett-Packard, Waldbronn, Germany). For signal 
generation 20-50 laser shots were added up in the single shot mode. 
2.5.9 Peptide stock solutions 
Carboxyfluorescein-labeled peptides were dissolved in DMSO at concentrations 
of 10 mM. These stock solutions were further diluted 1:10 in tert.-butyl alcohol/H2O 
(4:1). Peptide concentrations were determined by UV/VIS-spectroscopy of a 
further dilution (1:100) in Tris/HCl buffer (0.1 M, pH 8.8). Absorption was 
measured at a wavelength of 492 nm. Concentrations were calculated assuming a 
molar extinction coefficient of 75,000 l/(mol⋅cm).  
2.5.10 Cell culture 
The human myelomonocytic cell line THP-1 [198] was obtained from the 
Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) 
(Braunschweig, Germany). The cells were cultured in RPMI 1640 medium (PAN 
Biotech, Aidenbach, Germany) supplemented with 10% FBS (PAN Biotech) in a 
5% CO2 humidified atmosphere at 37°C. HEK 293T cells were cultured in IMDM 
medium (PAN Biotech, Aidenbach, Germany) supplemented with 10% FBS. The 
generation of the CD14-expressing Chinese hamster ovary (CHO)-K1 reporter cell 
line CHO/CD14/TLR2.elam.tac has been described in detail previously [199]. The 
cells were grown in RPMI 1640 medium containing 10% FBS, 400 µg/ml G418 and 
400 units/ml hygromycin B. Adherent cells were harvested with trypsin/EDTA 
(Biochrom, Berlin, Germany). Cells were passaged every third to fourth day. 
2.5.11 IL-8 ELISA 
THP-1 cells were suspended in RPMI medium containing 10% FBS and 
dispensed into 96-well culture plates (Sarstedt, Nürnbrecht, Germany) at a cell 
density of 4 x 104 cells per 200 µl of medium per well. Peptide amide stock 
solutions in DMSO were diluted 1:10 in tert.-butyl alcohol/H2O (4:1) prior to the 
addition to the cells. The amount of tert.-butyl alcohol in the cell culture never 
exceeded 1% (v/v). Solutions of peptide amides with enhanced solubility (peptide 
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11-24) were prepared without an intermittent dilution step in tert.-butyl alcohol/H2O 
(4:1). Cells were incubated with peptides at the indicated concentrations for 10 min 
at 37°C. Controls with peptide-free medium containing equal amounts of DMSO 
and tert.-butyl alcohol were included in each assay. Endotoxins were solubilized at 
a concentration of 5 mg/ml by sonication in endotoxin-free water for 7 min at 55°C. 
LPS was added to the samples at a concentration of 20 ng/ml. After further 
incubation for 5 h at 37°C cell-free supernatants were collected and stored at -
80°C prior to the quantification of IL-8 secretion by matched-pair ELISA (clone 
G265-5 and clone G265-8, BDPharMingen, San Diego, USA) according to the 
protocol provided by the manufacturer. 
2.5.12 TNF-α ELISA 
PMA was added to a THP-1 cell suspension from a 0.1 mg/ml stock solution to a 
final concentration of 30 ng/ml [200]. Cells were plated immediately into 96-well 
microtiter plates at a density of 4 x 104 cells per 200 µl of medium and allowed to 
differentiate for 72 h at 37°C. Before addition of the peptides, the cells were 
washed twice with medium. Due to the enhanced solubility of peptides applied in 
these assays, peptides were diluted directly into medium without a predilution step 
in tert.-butyl alcohol/H2O. After 10 min incubation with the indicated peptide LPS 
was added to the samples at a final concentration of 20 ng/ml. Supernatants were 
collected after 5 h incubation at 37°C and ELISA (clone MAb1 and clone MAb11, 
BDPharMingen) was performed according to the protocol provided by the 
manufacturer.  
2.5.13 Cell viability assay 
Cell viability was measured using the colorimetric 3-(4,5-dimethyl thiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) dye reduction assay. THP-1 cells were 
treated with the corresponding peptide amide and LPS for 5 h (see above). After 
removing 120 µl of the supernatant for ELISA analysis, cells were incubated with 
MTT (Sigma) at a concentration of 1 mg/ml for 4 h. The formazan product was 
solubilized with SDS (10% (m/v) in 10 mM HCl). The fraction of viable cells was 
determined by measuring the absorbance of each sample at 570 nm relative to the 
absorbance of untreated control cells using the microplate reader.  
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2.5.14 Detection of FITC-LPS-binding to biotinylated bead-immobilized peptides 
with laser scanning microscopy 
A suspension (100 µl) of high performance streptavidin-Sepharose in ethanol 
(20%, v/v) (Amersham Bioscience, Uppsla, Sweden) was washed three times with 
PBS and resuspended in 1 ml of PBS. A stock solution (10 mM) of biotinylated 
peptides in DMSO (2 µl) was incubated with 1 ml of the streptavidin-bead 
suspension for 60 min at 4°C on a shaker. Unbound peptides were removed by 
washing the beads three times with PBS and beads were resuspended in 350 µl 
PBS. 50 µl of this suspension were diluted with 950 µl of PBS in a 1.5 ml reaction 
tube. E. coli FITC-LPS serotype O111:B4 was solubilized to a concentration of 2 
mg/ml by sonication for 5 min at 50°C. 1 µl of this FITC-LPS solution was added to 
the 1 ml peptide loaded bead suspension and incubated for further 60 min at 4°C 
on a shaker. For competition experiments FITC-LPS was incubated with the beads 
in the presence of an unlabeled LPS-binding peptide (2 and 20 µM) or a 50-fold 
excess of unlabeled LPS. Subsequently the beads were washed three times with  
PBS/Tween20 (0.2%, v/v) and laser scanning microscopy was performed using an 
inverted LSM510 microscope (Carl Zeiss, Göttingen, Germany) equipped with a 
Plan-Apochromat 63 x 1.4 N. A.. Fluorescein was excited with a 488 nm argon-ion 
laser via an HFT 488 main beam-splitter. Fluorescence was detected with a BP 
505 - 550 nm band pass filter. 
2.5.15 Inhibition of the Limulus amebocyte lysate response to LPS 
Endotoxins were prepared according to the manufacturer`s protocol in 
endotoxin-free water to a concentration of 2 endotoxin units/ml. Peptides were 
prepared at varying concentrations in endotoxin-free water and 25 µl of the 
respective peptide solution were mixed with 25 µl of the LPS solution in a 96-well 
microtiter plate (Becton Dickinson, Franklin Lakes, USA) and incubated at 37°C on 
a shaker. After 45 min 25 µl of Limulus amebocyte lysate was added to each well 
and incubated for further 15 min. 50 µl of chromogenic substrate, prepared 
according to manufacturer’s specifications, were added and the reaction was 
stopped after 10 min by adding 100 µl of acetic acid (25%, v/v) to each well. 
Absorbance at 405 nm was determined using a microplate reader.  
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2.5.16 Inhibition of the cellular binding of FITC-LPS by CD14-derived peptides 
200 µl of RPMI 1640 containing FITC-conjugated LPS (1.2 µg/ml) was incubated 
either in the absence or presence of CD14-derived peptide amides for 5 min at 
37°C. Subsequently, 50 µl of these mixtures were added to CHO-CD14 cells 
seeded at a density of 1 x 106 cells/ml in 100 µl serum-containing RPMI 1640 in a 
96-well plate. After incubation, cells were washed twice with ice-cold medium, 
detached by trypsinization, suspended in ice-cold PBS and washed once in ice-
cold PBS. Binding of FITC-conjugated LPS to the cells was analysed by flow 
cytometry (BD FACSCalibur System, Becton Dickinson, Heidelberg, Germany). In 
each case, the median fluorescence intensity of 8,000 vital cells was determined. 
Vital cells were gated based on sideward and forward scatter. 
2.5.17 Determination of peptide conformation by CD-spectroscopy 
 CD spectra were measured on a JASCO J-720 dicrograph spectrometer (Jasco, 
Easton, MD, U.S.A.). Spectra were recorded at room temperature from 195 to 250 
nm at 0.2 nm intervals, with a spectral band width of 1 nm, and a scan speed of 20 
nm/min. Stock solutions of the peptide amides (1 mM) were prepared in 
1,1,1,3,3,3-hexafluoro-2-propanol and diluted to a concentration of 10 µM in 10 
mM sodium phosphate buffer, pH 7.4 or 10 mM sodium phosphate buffer (pH 7.4) 
diluted with trifluoroethanol (TFE) to yield 20% TFE (v/v). The spectra were 
corrected for buffer alone and the mean molar residual ellipticity ([Θ]) was plotted 
versus wavelength. The fractional helical content was estimated from the JFIT 
spectral deconvolution method (Lawrence Livermore National Laboratory, 
Livermore, CA).  
2.5.18 Site-directed mutagenesis 
The full length CD14 ORF was cloned into the pcDNA3 vector. Site-directed 
mutagenesis was performed using the QuikChange II site-directed Mutagenesis 
Kit (Stratagene Europe, Amsterdam, NL) according to the manufacturer’s 
instructions using the following primers: for the triple L to P exchange: 5’-
ctcagctaccggtaggcgccccgcgtgtgccagcgtactc-3’, 5’-
gagtacgctggcacacgcggggcgcctaccggtagctgag-3’; for the triple L to Q exchange: 5’-
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ctcagctacaggtaggcgcccagcgtgtgcaagcgtactc-3’, 5’-
gagtacgcttgcacacgctgggcgcctacctgtagctgag-3’ (obtained from biomers.net, Ulm, 
Germany). The correct sequences were verified by sequencing. The plasmid DNA 
was purified using the Endofree Plasmid Maxi Kit from Qiagen (Hilden, Germany). 
2.5.19 Analysis of the binding of FITC-LPS to HEK cells expressing wild type 
and mutant CD14. 
For transfection, HEK 293T cells were harvested with trypsin/EDTA washed with 
medium and suspended in medium containing the indicated plasmid. Cells were 
electroporated in 4 mm cuvettes (Peqlab, Erlangen, Germany) at a density of 2 x 
106 cells/ml, using a 15 millisecond pulse of 330 V and 1700 µF maximal 
resistance (Fischer Electroporator, Heidelberg, Germany). After electroporation, 
cells were incubated in the cuvettes for further 30 min and seeded at a density of 
500,000 cells per well in 6-well plates  (Sarstedt) or 40,000 cells per well in 8-well 
chambered cover glasses (Nunc, Wiesbaden, Germany) for further analysis. 
For flow cytometry, after 16 h at 37°C cells were trypsinized and seeded at a 
density of 100,000 per well in 96-well plates in serum-containing RPMI 1640. Cells 
were washed with medium, resuspended in 200 µl medium containing FITC-LPS 
(1 µg/ml) and incubated for 1 h at 4°C. Subsequently, cells were washed three 
times with medium, followed by incubation in 50 µl of ice-cold PBS/0.1% BSA (v/w) 
containing a polyclonal sheep anti-human CD14 antibody (5 µg/ml) (R & D 
Systems, Minneapolis, U.S.A)  for 1 h at 4°C. After washing three times in ice-cold 
PBS/0.1% BSA cells were incubated with 50 µl PBS/0.1% BSA containing a 
phycoerythrin-conjugated donkey anti-sheep secondary antibody (Dianova, 
Hamburg, Germany) (1:100 dilution) for 1 h at 4°C. Cells were washed three times 
with ice-cold PBS/0.1% BSA, suspended in ice-cold PBS/0.1% BSA, and 
measured immediately by flow cytometry (BD FACSCalibur System, Becton 
Dickinson, Heidelberg, Germany). In each case, the fluorescence of 10,000 vital 
cells was acquired. Vital cells were gated based on sideward and forward scatter. 
For confocal microscopy, electroporated HEK 293T cells were seeded at a 
density of 40,000/well in 8-well chambered cover glasses. One day later, cells 
were washed once with serum-containing RPMI 1640, followed by incubation with 
medium containing FITC-LPS on ice and stained for CD14 by indirect 
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immunofluorescence using the same reagents as described above. After staining 
living cells were imaged immediately. For double detection of FITC-LPS and 
phycoerythrin-labeled antibody the 488 nm line of an argon ion laser and the light 
of a 543 nm helium/neon laser were directed over an HFT UV/488/543/633 beam 
splitter and fluorescence was detected using an NFT 545 and an NFT 635 VIS 
beam splitter in combination with a BP 505-530 band pass filter for fluorescein 
detection and a BP 560-615 band pass filter for phycoerythrin detection.
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3 Ratiometric fluorescence-based LPS-sensing element 
This chapter was adapted from a manuscript in preparation. The author 
performed all experiments. Sensing element 1 was synthesized Dr. Rainer 
Fischer. 
3.1 Summary 
Lipopolysaccharide (LPS), the major compound of the outer leaflet of the cell 
wall of Gram-negative bacteria, is known to be responsible for the initiation of 
severe immunological disorders, such as sepsis and septic shock. We developed 
a novel FRET-based sensing element for detection of lipopolysaccharide. The 
sensing element is composed of the LPS-binding peptide corresponding to the 
amino acid sequence 81-100 of human CD14 terminally attached by 
tetramethylrhodamine (Tamra) and fluorescein (Fluo) residues serving as 
donor/acceptor pair for fluorescescence resonance energy transfer (FRET). Upon 
addition of LPS a FRET-based increase of Tamra fluorescence emission upon 
fluorescein excitation was observed and the ratio of the maximum fluorescence 
emission of the tetramethylrhodamine and fluorescein was determined for LPS-
detection. Discrimination of LPS versus other lipids was achieved by the 
comparison of the peptide and an analogue with distinct specificity due to 
alterations in the physicochemical properties using a detailed analysis of the 
fluorescence emission profile for both molecules.   
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3.2 Introduction 
Lipopolysaccharide, released from the outer membrane of Gram-negative 
bacteria when bacteria die or multiply, initiates a signaling cascade that induces 
the expression of inflammatory cytokines that may lead to Gram-negativ sepsis 
and septic shock [143]. Due to the high toxicity of LPS continuous effort is directed 
to the development of specific LPS-detection systems that are able to trace 
smallest amounts of LPS. Currently, the enzymatic Limulus amebocyte lysate 
(LAL) assay is used most widely to detect and quantify endotoxin in clinical and 
non clinical samples. However, there are several limitations of this method. The 
LAL assay, as most enzymatic tests are, is very sensitive but highly susceptible to 
changes in temperature and pH. Moreover, carbohydrate derivatives other than 
LPS, like β-glucans also react positively in this assay [201]. A variety of 
alternatives to or modifications of the LAL assay have been developed but none of 
them has established for biomedical applications, because of poor sensitivity or 
inconvenience [202].  
Ideally, a biomedical assay should enable the highly sensitive and specific 
detection of the analyte and be robust to changes in the molecular environment 
and prolonged storage. Sensors based on synthetic small molecules are 
considered a highly promising strategy for this purpose. A moiety for recognition is 
linked to a transducer that reports on the binding of the analyte. Förster resonance 
energy transfer (FRET) provides a sensitive fluorescence-based read-out for 
recognition elements in which binding of the analyte induces a conformational 
change. [203-208].  
For peptide-based recognition elements, a random coil to helix transition 
strongly changes the relative orientation of fluorophores attached to both ends of 
the helix thereby affecting the rate of energy transfer. For the detection of lipids a 
sensor based on a recombinant fusion protein in which the lipid-binding peptide 
derived from ActA was flanked by cyan and yellow fluorescent proteins at both 
ends was recently presented [209]. Binding of polyphosphorylated 
phosphoinositides induces a random coil to helix transition leading to a decrease 
of the FRET signal which is observed in the absence of the ligand. 
RATIOMETRIC FLUORESCENCE-BASED LPS-SENSING ELEMENT 
_________________________________________________________________________ 
 
63
For the α-helical antimicrobial peptide magainine with LPS-binding properties 
such a random coil to helix transition has also been described [210]. Recently, we 
identified a novel LPS-binding peptide from the LPS receptor CD14. We could 
show that in aqueous buffers this peptide is present as a random coil. Upon 
addition of trifluoroethanol (TFE), a helix promoting organic solvent, the peptide 
assumes an α-helical conformation corresponding to the conformation of the 
corresponding segment in the crystallized protein [178]. The peptide exhibited a 
strong LPS neutralizing activity in inhibiting the induction of the expression 
inflammatory cytokines. Moreover, an analogue with amino acid substitutions that 
increased the solubility had an IC50 value of about 10 µM in the LAL test. 
We therefore reasoned that the CD14-derived LPS-binding peptide and its 
analogue would provide promising recognition elements for the rational design of 
small molecule LPS sensing elements using FRET for the detection of binding. As 
fluorophores, carboxytetramethylrhodamine (Tamra) was attached to the N-
terminus and carboxyfluorescein to the C-terminus. It has been reported 
previously, that for this combination of fluorophores, when attached to a 
conformationally unconstrained peptide, the fluorescence of both fluorophores is 
quenched by a mechanism involving dimer formation [211]. Any conformational 
change of the peptide that induces the separation of the fluorophores decreases 
the quenching so that FRET may be detected. Based on this principle, binding of 
an antibody to a 13-peptide epitope labeled with these fluorophores was detected. 
We here demonstrate that a doubly labeled CD14-derived peptide as well a 
similar ligand-depended increase in FRET was observed. The CD14-derived 
peptide and its analogue were synthesized using optimized protocols for the 
generation of doubly labeled peptides [176]. In the presence of LPS both 
fluorescent peptides alter their spectral characteristics. Selectivity of these sensing 
elements was established by probing the response to a series of lipid and 
lipopeptides. Detection of LPS was achieved for as little as 150 nM of LPS, 
thereby exceeding previously published LPS sensors by a factor of about 100 
[212]. 
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3.3 Results 
3.3.1 Development of a fluorescence-based LPS-sensing element 
The native sequence of the CD14-derived peptide and an analogue with higher 
solubility were selected as recognition elements for a small molecule LPS sensing 
element (Table 3.1).  
 
Table 3.1 Doubly labeled fluorescent peptides used as FRET-based LPS-sensing elements 
(SE). SE 1 corresponds to the amino acid positions 81-100 of mature human CD14. SE 2, an 
analogue of SE 1 containing amino acid substitutions at positions 3, 5, 9, 13, 17 was designed to 
enhance sensor solubility and sensitivity. 5(6)-Carboxyfluorescein is attached via the α-amino 
group of the C-terminal lysine residue and the peptide was assembled on the ε-amino group [176]. 
Carboxytetramethylrhodamine was attached to the N-terminus of the peptide amides.  
 Peptide Sequence 
SE 1 Tamra-QVPAQLLVGALRVLAYSRLK-εK(αFluo)-NH2 
SE 2 Tamra-QVAAKLLVKALRKLAYKRLK-εK(αFluo)-NH2 
SE 3 Tamra-QVPAQLLVGALRVLAYSRLK-NH2 
 
The native sequence corresponds to amino acids 81-100 of human CD14. In the 
analogue, residues 5, 9, 13, 17 of the native peptide (Voss et al., 2005) were 
mutated for lysine residues and residue 3 for a proline residue. It was shown by an 
alanine scan that these residues were not required for the LPS-neutralizing 
activity. We reasoned that the increased solubility would be beneficial to the 
application of this peptide as a sensor. Furthermore, we were interested to learn 
whether both molecules exhibited different sensitivity for LPS and possibly also 
different specificity for related amphiphilic ligands, due to the enhanced positive 
net charge of SE 2.  
When performing fluorescence spectrometry in buffer, both molecules displayed 
a two-peak spectrum upon excitation at 492 nm (excitation of fluorescein) (Figure 
3.1A and 3.1B). Upon addition of lipopolysaccharide (E.coli, serotype O111:B4) 
both sensing elements altered their spectral characteristics leading to a reduced 
fluorescence emission at 520 nm and a significantly enhanced emission at 588 
nm, indicating an increase in FRET. For the lipid sensor based on ActA the 
fluorophore separation due to ligand binding resulted in a decrease in FRET [209]. 
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The spectral changes in the presence of LPS should therefore be a consequence 
of dimer dequenching due to spatial separation of fluorophores and due to 
environment-dependent changes in fluorescence quantum yield caused by 
interaction of the fluorophores with the ligand. The latter possibility was addressed 
by the synthesis of a SE 1 analogue (SE 3) that lacks the fluorescein moiety 
(Figure 3.1C). In spite of the absence of a potential energy donor, in the ligand-
free state SE 3 exhibited a stronger rhodamine emission than SE 1, demonstrating 
that the rhodamine fluorescence was nearly completely quenched due to dimer 
formation. The presence of environment-dependent effects on quantum yield was 
confirmed by the increase in fluorescence upon addition of LPS. 
 
 
0
10
20
30
40
50
500 550 600 650
A
SE 1
SE 1 + LPS
wavelength [nm]
flu
or
es
ce
nc
e 
in
te
ns
ity
 [a
.u
.]
 
0
10
20
30
40
50
500 550 600 650
B
SE 2
SE 2 + LPS
wavelength [nm]
flu
or
es
ce
nc
e 
in
te
ns
ity
 [a
.u
.]
 
RATIOMETRIC FLUORESCENCE-BASED LPS-SENSING ELEMENT 
_________________________________________________________________________ 
 
66 
C
SE 3
SE 1
SE 1 + LPS
SE 3 + LPS
flu
or
es
ce
nc
e 
in
te
ns
ity
 [a
.u
.]
wavelength [nm]
0
10
20
30
40
50
500 550 600 650
  
 
D
0
4
8
12
no ligand LPS proteinase K
SE 1
SE 2
ra
tio
 fl
uo
re
sc
en
ce
 e
m
is
si
on
 
58
8 
/ 5
20
 
 
Figure 3.1 Spectral characteristics of the small molecule LPS sensing elements. Fluorescence 
emission spectra of sensor 1 (A) and 2 (B) (100 nM) in PBS in the absence and presence of LPS (2 
µM). (C) Fluorescence emission spectra of SE 1 and 3 (100 nM) in PBS in the absence and 
presence of LPS (2 µM). Probes were excited at 492 nm and an emission spectrum was recorded 
as described in the method section. (D) Ratio of the fluorescence emissions at 588 and 520 nm of 
SE 1 and 2 in PBS alone, in the presence of LPS and after proteinase K treatment (10 µg/ml).  
 
To determine the maximal loss of quenching of fluorescein fluorescence and to 
obtain further information on the dimer induced quenching of rhodamine 
fluorescence SE 1 was digested by proteinase K (Figure 3.2). Proteolysis induced 
a strong increase in the intensity of the fluorescein emission at 520 nm (Figure 
3.2A).  
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Figure 3.2 Fluorescence emission spectra of SE 1 (100 nM) in PBS in the absence and 
presence of proteinase K (10 µg/ml). The digestion was carried out at 37°C for 3 h. The spectra 
were measured in PBS. Probes were excited at 492 nm (A) or 541 nm (B) which represent the 
excitation optima for fluorescein and tetramethylrhodamine, respectively. The emission spectra 
were recorded and described in the method section. 
 
The maximum emission intensity of Tamra was achieved when the proteinase K 
digested sample was excited at 541 nm (Figure 3.2B), the excitation maximum of 
this dye. This value is about three times higher than the value of the undigested 
SE 1 in the presence of 2 µM LPS.  
For the single labeled peptide, binding of LPS already led to an environment-
dependent increase in fluorescence quantum yield. However, a determination of 
the LPS-binding due to a mere increase in fluorescence intensity is little robust to 
changes of the sensor concentration. In contrast, for doubly labeled sensing 
elements a specific ratiometric value of the emission intensities could be obtained 
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for each of the functional states of the sensing elements (ligand-free or LPS-
bound) which is independent on the sensor concentration (Figure 3.1D). 
Interestingly, the maximum emission ratios for both sensing elements in the LPS-
free as well as in the LPS-bound state also differed significantly. For SE 2 the ratio 
was larger than for SE 1. 
A putative mechanism for the detection of LPS is shown schematically in Figure 
3.3. The efficiency of FRET is highly sensitive to the distance between the 
fluorophores, and an eicosapeptide is sufficiently long to maintain fluorophore 
separation.  
 
LPS
CD14
81-100
 
 
Figure 3.3 Schematic representations of the SE and its putative conformational states in the 
absence and presence of LPS. The SE is composed of a 20-peptide moiety, corresponding to the 
LPS-binding site of CD14 (amino acids 81-100), flanked by N-terminal Tamra and C-terminal 
fluorescein. Without ligand, both fluorophores form an intramolecular dimer resulting in a significant 
quenching of the fluorescence emission. The LPS-induced structural change leads to a fluorophore 
separation so that fluorescence resonance energy transfer could be observed.  
 
Next, the dependence of the LPS-induced increase in the emission ratios on the 
concentration of LPS was determined (Figure 3.4). For SE 1 the ratio increased 
linearly with concentration over a concentration range of up to 1.5 µM LPS. 
Saturation was observed at concentrations higher than 2 µM. The detection limit of 
LPS was about 150 nM. SE 2 exhibited a steeper increase in the ratiometric 
values, at concentrations between 0.5 and 1.5 µM and larger maximum ratiometric 
values, but also a higher detection limit (about 0.5 µM) compared to SE 1 (Figure 
3.4C).  
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Figure 3.4 Fluorescence emission spectra of SE 1 (A) and SE 2 (B) (100 nm) in the presence of 
varying concentrations of LPS (0, 0.094, 0.188, 0.375, 0.75, 1.5, and 3 µM). (C) Ratios of the 
fluorescence emissions at 588 and 520 nm of SE 1 and 2. Probes were incubated for 1 h at 37°C 
on a shaker and excited at 492 nm in PBS. The emission spectra were recorded as described in 
the method section. 
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3.3.2 Determination of the specificity of sensing elements 1 and 2 
Beside sensitivity, a sensor is characterized by its specificity enabling the 
recognition of the ligand without interference by molecules with similar 
physicochemical characteristics. To determine whether the sensing elements were 
able to specifically detect LPS, their fluorescence emission spectra were recorded 
in the presence of increasing concentrations of several amphipathic lipids. These 
include LPS from Escherichia coli, the neutral and negatively charged 
phospholipids POPC and POPG, and di- and triacylated lipopeptides (Table 3.2). 
Latter were selected due to their high immune-stimulating properties [28;78-
81;87;213] and outstanding relevance as immune adjuvants [83-85;89;214-219] 
such as the water soluble lipopeptide Pam3Cys-SK4 [82;220-224].  
 
Table 3.2 Amphipathic compounds tested in the presence of SE 1 and 2. 
Lipid compound Sequence / denotation 
LPS E. coli O111:B4 
Pam3Cys-SK4 Pam3Cys-SKKKK 
BCI-009 Pam3Cys-(VPGVG)4VPGKG-NH2 
MALP2 Pam2Cys-GNNDESNISFKEK 
POPC phosphatidylcholine 
POPG phosphatidylglycerol 
 
Since both sensing elements exhibit characteristic differences in the recognition 
of varying concentrations of LPS (Figure 3.2) we hypothesized that the sensing 
elements also differentially recognize different lipids. Figure 3.5 shows the 
fluorescence emission ratios of SE 1 and 2 as a function of lipid concentration. For 
both sensing elements, the steepest increase and the highest ratiometric values 
were obtained in the presence of LPS and the lipopeptide Pam3Cys-SK4. In 
contrast, the maximum values evoked by BCI-009, MALP-2 and the phospholipid 
POPC were significantly lower (3, 4 and 1, respectively) and the curves exhibited a 
flatter increase. Interestingly, POPG was differentially recognized by the sensing 
elements. Whereas SE 2 exhibited a steeper increase of the ratiometric values 
and a higher maximum value, SE 1 exhibited a curve comparable to that for 
MALP-2. In contrast, the neutral phospholipid POPC was detected neither by SE 1 
nor by SE 2. 
 
RATIOMETRIC FLUORESCENCE-BASED LPS-SENSING ELEMENT 
_________________________________________________________________________ 
 
71
 
ra
tio
 fl
uo
re
sc
en
ce
 e
m
is
si
on
58
8/
52
0 
of
 S
E
 1
concentration of lipid [µM]
LPS
P CSK3 4
BCI009
Malp-2
POPC
POPG
A
0
3
6
9
0 10 20 30 40 50
 
ra
tio
 fl
uo
re
sc
en
ce
 e
m
is
si
on
58
8/
52
0 
of
 S
E
 2
concentration of lipid [µM]
B
0
3
6
9
0 10 20 30 40 50
 
 
Figure 3.5 Dependence of the fluorescence emission ratios of SE 1 (100 nM) (A) and 2 (B) on 
concentration for various amphipathic compounds. The spectra were measured in PBS. Probes 
were excited at 492 nm and an emission spectrum was recorded as described in the methods 
section. 
 
Next, we plotted the ratiometric values as a function of the fluorescence 
emission at 588 nm (Figure 3.6) to reveal whether the concentration dependent 
alterations of the ratio and the corresponding fluorescence emission at 588 nm 
behave in a distinctive manner. The obtained curves can be consulted for ligand 
discrimination if they are sufficiently separated.  
LPS evoked the steepest increase in the ratio values in comparison to all other 
lipids resulting in a separation of its curves from that of POPC, POPG, Malp-2 and 
BCI-009 when using SE 1. For lipopeptide BCI-009, the curve is even separated 
from all other lipids, due to a significant weaker increase in the emission ratio. In 
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contrast, intersection was observed between LPS and Pam3Cys-SK4. However the 
lipopeptide exhibited a weaker increase and significantly enhanced emission 
values at 588 nm at higher concentrations resulting in a pronounced right shift of 
the curve, compared to that from LPS.  
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Figure 3.6 Ratio of the fluorescence emission of (A) SE 1 and (B) SE 2 (100 nM) in the 
presence of increasing concentrations of lipids as a function of the fluorescence emission at 588 
nm. The spectra were measured in PBS. Probes were excited at 492 nm and an emission 
spectrum was recorded as described in the methods section. 
 
To attain further discrimination the ratiometric values evoked by increasing 
concentrations of lipids of SE 1 and 2 were plotted against each other (Figure 3.7). 
For most lipids both sensing elements exhibited a comparable ratiometric signal 
which was represented by a linear increase of the respective curve. However, for 
POPG the sensitivity of SE 2 was significantly enhanced compared to SE 1 which 
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is represented by a steeper increase of the fluorescence ratio at POPG 
concentrations below 5 µM. 
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Figure 3.7 Fluorescence emission ratios of SE 1 plotted versus the flurescence emission ratio of 
SE 2 in the absence or presence of increasing concentration of lipid compounds.  
3.4 Discussion 
The peptide corresponding to amino acid 81 to 100 of human CD14 tagged N-
terminally with Tamra and C-terminally with fluorescein exhibited a significant 
change in FRET in the presence of LPS and therefore could be applied as a 
FRET-based sensing element for LPS. Previously, we identified a part of LPS-
binding domain of the LPS-receptor CD14. The corresponding peptide was able to 
bind to LPS from E. coli, serotype O111:B4, thereby neutralizing the LPS-induced 
cytokine expression of THP-1 cells. Three leucines at positions 7, 11 and 14 were 
found to be essential residues. Under mild secondary structure inducing conditions 
(20% TFA) this peptide exhibited an α-helical conformation which is also observed 
for other LPS-binding peptides when binding to LPS. In this report we show, that 
the binding of LPS to the doubly labeled peptide and to an analogue with 
enhanced amphipathicity caused a change of the fluorescence emission spectrum. 
The ratio from the fluorescence emissions at 588 nm and 520 nm was determined 
and selected for ligand recognition.  
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Although several other lipids induced an increase in this ratiometric signal of our 
sensing molecules we observed distinct spectral characteristics for these 
compounds which were selected for specific ligand detection. The lipopeptide 
Pam3Cys-SK4, for instance induced concentration-dependent changes of the 
ratiometric signals of SE 1 and 2 comparable to that of LPS. However, in contrast 
to LPS, the lipopeptide evoked a significantly enhanced fluorescence emission at 
588 nm at high ligand concentrations, which resulted in a significant separation of 
the curve in Figure 3.6. In comparison to LPS and Pam3Cys-SK4, the hydrophobic 
lipopeptide BCI-009 as well as the diacylated lipopeptide MALP-2 evoked 
significantly lower ratiometric values. When the ratio of the fluorescence emission 
of the analyzed lipids was plotted against the excitation at 588 nm (Figure 3.6) 
discrimination between the two hydrophobic lipopeptides BCI-009 and MALP-2 
and LPS was possible in a range between 5 and 50 µM. 
For most lipids tested the spectral changes for SE 1 and 2 were similar. 
However, for POPG, SE 2 exhibited higher ratiometric signals at low POPG 
concentrations than SE 1 resulting in a characteristic curve when the ratiometric 
values of SE 1 were plotted against those of SE 2. As shown in section 2, 
hydrophobic residues contribute to the interaction between LPS and the CD14-
derived peptides. The enhanced sensitivity of SE 2 for POPG as well as the 
inability for both sensing elements to detect the neutral phospholipid POPC might 
therefore indicate that electrostatic rather than hydrophobic interactions are 
involved in the recognition of phospholipids by our sensing element. Due to these 
properties it might be possible to distinguish between the effects of negative and 
neutral phospholipids. In addition, our observations demonstrate that alterations of 
the physicochemical properties of the sensing element influence its sensitivity and 
specificity.  
It is known that LPS evokes immune responses when injected at nanogram 
quantities [99]. Since the LAL assay is able to detect these small amounts of LPS 
it represents an appropriate method for LPS detection in this concentration range. 
However, the usage of the LAL assay is compromised by limited specificity. 
Despite of the lower sensitivity of our CD14-derived sensing system, sensors in 
which the recognition element consists of a peptide have the advantage that their 
specificity can be varied easily by altering the binding-sequence, as we could 
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show in this study. Therefore, the peptide based sensing element constitutes a 
starting point for the development of further, more sensitive and selective sensors.  
In addition to LPS, CD14 also contributes to the activation of cells by 
lipopeptides [44;150] and binds to a variety of lipid compounds, including 
phosphatidylinositides [225]. We cannot completely exclude whether the 
corresponding binding region in the native CD14 might also be involved in the 
recognition of ligands other than LPS. For this reason, the CD14-derived peptides 
might also interact with other CD14-binding molecules in addition to LPS. 
However, as revealed by in vitro assays, the peptide amide CD14 (81-100) 
showed only weak inhibitory activity against the lipopeptide Pam3Cys-SK4 
indicating for an LPS-specific recognition element. 
The peptide-based sensing system provides a novel opportunity to detect and 
distinguish lipids. By applying SE 1 we were not able to specifically recognize LPS, 
because several other lipids were able to evoke signals almost comparable to that 
of LPS. However, specific LPS recognition in the concentration range of 5 to 50 
µM was achieved by the application of two sequentially differing sensing elements 
SE 1 and SE 2 which exhibit distinct physicochemical properties and by analysing 
the data in a way that considers the characteristics spectral changes evoked by 
the induced by the individual lipid compounds.  
3.5 Materials and methods 
3.5.1 Reagents 
Lipopolysaccharide from E. coli (phenol extracted and purified by ion-exchange 
chromatography) was from Sigma (Taufkirchen, Germany). Three synthetic 
lipopeptides were from EMC microcollections (Tübingen, Germany): The water 
soluble S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-N-palmitoyl-(R)-cysteinyl-(S)-seryl-
tetralysine (Pam3Cys-SKKKK), S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-N-palmitoyl-
(R)-cysteinyl-(VPGVG)4VPGKG-NH2 (Pam3Cys-(VPGVG)4VPGKG-NH2) (BCI-009) 
and the diacylated lipopeptide  S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-
cysteinyl-GNNDESNISFKEK (Pam2Cys-GNNDESNISFKEK) with the sequence of 
MALP-2 [75]. Standard chemicals were from Fluka (Deisenhofen, Germany) and 
Merck (Darmstadt, Germany). Fmoc-amino acids were purchased from 
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Novabiochem (Läufelfingen, Schweiz), Senn Chemicals (Dielsdorf, Switzerland), 
and Orpegen Pharma (Heidelberg, Germany). Fmoc-Lys(Dde)-OH was from 
Novabiochem. The mixtures of the isomers of 5(6)-carboxyfluorescein (Fluo) and 
5(6)-carboxytetramethylrhodamine (Tamra)-N-succinimidylester were from Fluka. 
1-Palmitoyl-2-oleoyl-phosphatidylcholine and 1-palmitoyl-2-2-oleoyl-
phosphatidylglycerol were from Avanti Polar Lipids / Otto Nordwald GmbH 
(Hamburg, Germany). 
3.5.2 Solid-phase synthesis of Tamra-CD14 (81-100)-Fluo. 
The doubly labeled peptides Tamra-QVPAQLLVGALRVLAYSRLK-εK(αFluo)-
NH2 and Tamra-QVAAKLLVKALRKLAYKRLK-εK(αFluo)-NH2 (Table 3.1) were 
synthesized using a previously described (Fluo(Trt)-Lys-Rink amide resin [176]. 
The carboxyfluorescein is attached to the Nα−amino group of the resin bound 
lysine and the peptide was assembled on the Nε−amino group of the lysine 
residue. The resin-bound and side-chain protected peptide (5 µmol) was then 
reacted with   5(6)-carboxytetramethylrhodamine-N-succinimidyl ester (10 µmol, 
5.3 mg) in DMF (200 µl) containing DIPEA (2 µmol, 4.3 µl). After 16 h, the resin 
was thoroughly washed. Peptides were cleaved off the resin and side chains 
deprotected by treatment with trifluoroacetic acid/triisopropylsilane/H2O 
(92.5:2.5:2.5:5, v/v/v/v) for 4 h. Crude peptides were precipitated by adding cold 
diethyl ether (-20°C). The precipitated peptides were collected by centrifugation 
and resuspended in cold diethyl ether. This procedure was repeated twice. Finally 
the peptides listed in Table 3.1 were dissolved in ACN/water, lyophilized and 
analyzed by HPLC and MALDI-MS. Tamra-QVPAQLLVGALRVLAYSRLK-
εK(αFluo)-NH2: purity 80% (HPLC, 214 nm), calc. [M+H]+ = 3094.7 Da, exp. 
[M+H]+ = 3094.6  Da. Tamra-QVAAKLLVKALRKLAYKRLK-εK(αFluo)-NH2: purity 
80% (HPLC, 214 nm), calc. [M+H]+ = 3209.9 Da, exp. [M+H]+ = 3209.5  Da (Table 
3.3). The fluorescent peptide was then purified by preparative HPLC for 
spectroscopic characterization. 
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Table 3.3 Characterization of sensing elements 1 and 2 by MALDI-TOF MS and HPLC. 
 
 
 
3.5.3 HPLC 
Peptides and conjugates with fluorophores (Table 3.1) were analyzed by 
analytical RP-HPLC (Waters 600 System, Eschborn, Germany) with a solvent 
system gradient: water/0.1% TFA (solvent A) and acetonitrile/0.1% TFA (solvent 
B) using an analytical HPLC column (Nucleosil 100, 250 x 2 mm, C18 column, 5 
µm particle diameter; Grom, Herrenberg, Germany) with a linear gradient from 
10% B to 100% B within 30 min (flow rate: 0.3 ml/min) and detection at 214 nm. 
Peptides were purified by preparative RP-HPLC (Nucleosil 300, 250 x 20 mm, C18 
column, 10 µm particle diameter; Grom, Herrenberg, Germany) on a Gilson 
preparative system (Bad Camberg, Germany), equipped with a 321 Pump and a 
156 UV/Vis detector at a flow rate of 10 ml/min. Gradients were adjusted 
according to the elution profiles and peak profiles obtained from the analytical 
HPLC chromatograms. Peptide purities of all peptides used in this study were 
>98% (214 nm, HPLC). 
3.5.4 MALDI-TOF MS 
1 µl of DHAP matrix (20 mg of DHAP, 5 mg of ammonium citrate in 1 ml of 
isopropyl alcohol/H2O (4:1, v/v)) was mixed with 1 µl of each sample (dissolved in 
ACN/water (1:1) at a concentration of 1 mg/ml) on a gold target. Measurements 
were performed using a MALDI time-of-flight system (G2025A, Hewlett-Packard, 
Waldbronn, Germany). For signal generation 20-40 laser shots were added up in 
the single shot mode. 
Sensing 
element 
Sequence [M+H]+ 
[Da] 
Retention time 
[min] 
SE 1 Tamra-QVPAQLLVGALRVLAYSRLK-εK(αFluo)-NH2 3094.6 26.0 
SE 2 Tamra-QVAAKLLVKALRKLAYKRLK-εK(αFluo)-NH2 3209.5 23.2 
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3.5.5 Peptide stock solutions 
Doubly-labeled peptides (Table 3.3) were dissolved in DMSO at concentrations 
of 10 mM. Peptide concentrations were determined by UV/VIS-spectroscopy of a 
further dilution (1:100) in MeOH. Absorptions were measured at a wavelength of 
540 nm (ε = 95,000 l/(mol⋅cm)). 
3.5.6 Preparation of lipids and fluorescence spectroscopy. 
Lipopeptides were suspended in DMSO (10 mM), lipopolysaccharides in water 
(5 mg/ml) and phospholipids in chloroform (32 mM). All lipids were sonicated at 40 
W using a Sonorex Super RK 510H sonicator (Bandelin, Berlin, Germany) until 
solubilization as indicated by a clear solution. Doubly-labeled peptides were 
diluted in PBS to a concentration of 100 nM. The doubly-labeled peptide solution 
(400 µl) was transferred to an Eppendorf reaction tube and lipids (Table 3.2) were 
added to a final concentration of 2 µM. Titration experiments were performed in 
96-well round bottom microtiter plates. The samples were incubated for 10 min on 
ice and subsequently for at least 45 min at 37°C on a shaker. After incubation 
probes were subjected to fluorescence spectrometry performed in quartz cuvettes 
using an LS 50B luminescence spectrometer (Perkin-Elmer, Norwalk, CT, USA). 
The excitation wavelength was set to 492 nm; emission scans from 450 to 800 nm 
were recorded, and the ratio of emission intensities of 588 versus 520 was 
determined. For proteinase K treatment, a 100 nM solution of sensing element 1 
(SE 1, Table 3.3) was incubated with 10 µg/ml of proteinase K for 3 h. Aliquots 
were taken and the emission spectra of the sample were recorded immediately
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4 The state of aggregation determines the bioactivity of 
lipopeptides 
This chapter was adapted from a manuscript submitted to European Journal of 
Immunology. The author of this thesis performed all experiments. Lipopeptides 
used for the experiments were from EMC microcollections (Tübingen, Germany). 
4.1 Summary 
Lipoproteins are major components of the cell wall of Gram-positive and  
-negative bacteria and activate cells of the innate immune system via 
heterodimers of Toll-like receptor (TLR) 2 with either TLR1 or TLR6. In spite of the 
progress in understanding TLR-dependent signal transduction and the 
pathophysiological relevance of TLR2, the molecular basis of ligand recognition by 
this receptor is only poorly defined. The bioactivity of lipopeptides strongly 
depends on the dilution protocol. Analysis of fluorescently labeled analogues of 
the synthetic amphiphilic lipohexapeptide Pam3Cys-Ser-Lys4 by fluorescence 
correlation spectroscopy revealed that these compounds form aggregates in 
solution. Dilution into protein-and serum-free buffers leads to a complete loss of 
activity due to formation of large and highly heterogeneous aggregates. When 
diluted into BSA or serum-containing buffers, the size of the aggregates was 
strongly reduced and indicative of an interaction of the lipopeptides with protein. 
Moreover, the aggregate size depended on the peptide moiety and correlated 
negatively with the bioactivity of the peptide. Dilution of DMSO stock solutions of 
lipopeptides with tert.-butyl alcohol/H2O (4:1) prior to the preparation of the final 
working solutions eliminated these peptide-dependent differences in aggregate 
size resulting in comparable bioactivities. This result is highly relevant for the 
analysis of structure-activity relationships of lipopeptide-dependent TLR2 
activation.  
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4.2 Introduction  
Due to the highly repetitive structure and complex physicochemical and 
conformational properties of most TLR ligands, the exact nature of the molecular 
interaction between receptors and agonists has remained elusive for all TLR 
subtypes as did the molecular mechanism of receptor activation. For lipopeptide 
and lipopolysaccharide ligands, amphiphilicity leads to the rapid insertion of these 
molecules into cellular membranes [226-228]. 
For TLR2-dependent signal transduction, synthetic lipopeptides provide a rich 
source of highly diverse structures to explore the structure-activity relationships of 
TLR2-dependent activation. Analogues of the well known synthetic adjuvants S-
[2,3-bis(palmitoyloxy)-(2RS)-propyl]-N-palmitoyl-(R)-cysteinyl (Pam3Cys) peptides 
[79;82;216] with modifications of the lipid as well as the peptide moiety can be 
efficiently generated by combinatorial solid-phase organic chemistry [94;196]. 
When testing the induction of expression of the cytokine IL-8 by synthetic 
lipopeptides that differed with respect to their peptide moiety we discovered that 
the dissolution protocol affected the bioactivity of some lipopeptides. It had been 
described previously, that Pam3Cys-conjugates form vesicular or tubular 
aggregates of different size in aqueous solutions depending on the configuration of 
the glycerol moiety and the head group [229]. We therefore wondered, whether the 
observed dissolution-dependent differences correlated with a differential tendency 
of the respective analogues to form aggregates. For LPS it was shown, that the 
aggregation as well as the type of aggregate structure is essential for activity and 
cell binding properties [230-234].  
To detect the presence of aggregates in solution confocal fluorescence correlation 
spectroscopy (FCS) [235] was applied to a limited set of fluorescently labeled 
lipopeptide analogous. FCS is a highly sensitive tool to derive information on 
molecular interactions, particle size and the number of fluorescent particles from 
the time-correlated analysis of fluctuations of a fluorescence signal. For example, 
fluorescence fluctuation spectroscopy was formerly used to detect e.g. 
aggregation between oligonucleotides and polycationic polymers [236]. In addition, 
FCS provides a quick and simple method for the determination of aggregates in 
solution. 
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Using FCS our experiments revealed that the observed dissolution-dependent 
differences were in fact due to the formation of aggregates of different size. 
Introduction of an additional dilution step in tert.-butyl alcohol/H2O (4:1) decreased 
the aggregate size and increased the biological activity. The optimized dissolution 
protocol eliminates a major uncertainty in comparing the biological activity of TLR2 
ligands. Therefore, our results generate a solid experimental basis for the analysis 
of structure-activity relationships that reliably reflect the capacity of the ligands to 
activate the receptor. 
 
4.3 Results 
4.3.1 Dissolution-dependent biological activity of lipopeptides.. 
It had been shown previously for a collection of synthetic lipohexapeptide 
analogues carrying the head group agonist Pam3Cys, that the peptide moiety has 
little influence on the TLR2 agonistic bioactivity [94]. When testing two different 
Pam3Cys peptide analogues LP1 and LP2 with respect to the induction of IL-8 
expression in THP-1 cells, we were therefore surprised to find that LP1 showed 
little agonistic activity whereas LP2 exhibited significant activity (Figure 4.1). LP1 
contains the ovalbumine derived epitope of the MHC-I-complex H-2Kb and a 
proline spacer between the lipid and the epitope whereas LP2 contains an 
arbitrarily constituted peptide sequence and a pentaproline spacer (Table 4.1)  
 
Table 4.1 Lipopeptide analogues tested for agonistic activity. Fluorescently labeled derivatives 
of LP1 and LP2 (Rh-LP1 and Rh-LP2) were in addition investigated by FCS.  
Carboxytetramethylrhodamine (Tamra) was covalently linked to the ε-amino group of the lysine 
residue in the peptide moiety.  
Lipopeptide Sequence 
LP1 P3C-PPPPPSIINFEKL 
LP2 P3C-PPPPPPFEDIYKN 
Rh-LP1 P3C-PPPPPSIINFEK(Tamra)L 
Rh-LP2 P3C-PPPPPPFEDIYK(Tamra)N 
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Figure 4.1 Agonistic activities of differently diluted lipopeptides. Lipopeptide stock solutions  
(1 mM in DMSO) were diluted either 1:20 in tert.-butyl alcohol/H2O (4:1) or DMSO. These solutions 
were further diluted 1:500 with RPMI/10% FBS and subsequently 1:10 to a final concentration of 10 
nM with medium containing THP-1 cells. THP-1 cells were incubated with LP1 (A) and LP2 (B) for 
16 h. IL-8 secretion was measured by matched-paired ELISA. Error bars represent the mean 
deviations of triplicates. 
 
It is well known that for amphiphilic molecules, the dissolution protocol is a 
critical first step. Even though clear solutions were prepared for both lipopeptides, 
we therefore suspected differences in the dissolution behaviour of these 
lipopeptides as the basis for this observation. As an alternative to the preparation 
of highly concentrated 1 mM DMSO stock solutions we had previously used a 
dilution of the DMSO stock solutions of lipopeptides into tert.-butyl alcohol/H2O 
(4:1, v/v) as a dissolution protocol. When such solutions of fluorescently labeled 
lipopeptides were pipetted onto hydrophobic surfaces and dried, a highly 
homogeneous surface functionalization was obtained, indicative of a good 
dissolution of the lipopeptides [237]. We therefore introduced a further 1:20 dilution 
step of the DMSO stock solution into tert.-butyl alcohol/H2O (4:1, v/v)). The 
agonistic activity of lipopeptide 1 (LP1) was in fact significantly enhanced using 
tert.-butyl alcohol/H2O (4:1) as a solvent prior to its addition to the FBS-containing 
tissue culture medium. In contrast, for LP2, dilution into tert.-butyl alcohol/H2O 
(4:1) yielded only a minor increase in bioactivity. DMSO and tert.-butyl alcohol 
possess cytotoxic activities when present in the cell culture medium at 
concentrations exceeding 0.2 or 2% respectively (own observations). In our 
experiments the amount of the solvents was two orders of magnitude below the 
toxic concentrations and did therefore not influence the viability of the THP-1 cells. 
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4.3.2 Aggregation of differently diluted LPs monitored by single molecule 
detection. 
To determine whether the increase in bioactivity of the tert.-BuOH/H2O treated 
LP1 was due to a change in aggregation, fluorescence correlation spectroscopy of 
5(6)-carboxytetramethylrhodamine-labeled analogues of these lipopeptides (Rh-
LP1 and Rh-LP2) was performed. Changes in the hydrodynamic radius of 
molecules, e. g. due to formation of molecular aggregates constitute themselves 
as a shift of the autocorrelation function towards longer diffusional autocorrelation 
times. However, as the diffusion constant D scales inversely with the cubic root of 
the molecular weight, detectable shifts require a substantial mass increase.  
First, we investigated whether the fluorescently labeled lipopeptides exhibited 
the same dilution-dependent cell-activating properties as their non-fluorescent 
counterparts (Figure 4.2A). The agonistic activity of Rh-LP1, the fluorescently 
labeled analogue of LP1, strongly depends on the dilution protocol in 
correspondence to the unlabeled lipopeptide. In contrast, the dilution protocol did 
not influence the biological activity of Rh-LP2 as determined for its non-fluorescent 
analogue. For LPS it was shown that several proteins, including LPS-binding 
protein, sCD14 and albumin are involved in binding, transport and disaggregation 
of LPS aggregates prior receptor activation [185;187;188;238]. Due to the fact, 
that these LPS binding molecules are present in FBS we also investigated whether 
dilution of the lipopeptide solutions into buffer containing BSA alone yielded the 
same dependence of activity on the additional tert.-butyl alcohol/H2O (4:1) dilution 
step. A high activity of LP demonstrated that addition of BSA to the buffer is 
sufficient to achieve an efficient lipopeptide-mediated activation of cells (Figure 
4.2B) whereas the dilution of lipopeptides in buffer without protein completely 
abolishes lipopeptide activity (see Figure 4.6). Therefore BSA is a minimal 
requirement for an active state of the lipopeptides. The general effect of the 
dilution protocol (Figure 4.3) for both lipopeptides was the same and the overall 
activity of both lipopeptides was lower in the presence of BSA than in the presence 
of FBS. 
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Figure 4.2 Determination of the agonistic activity of differently diluted Tamra-labeled analogues 
of lipopeptides LP1 and LP2. THP-1 cells were incubated with 10 nM of either tert.-butyl 
alcohol/H2O (4:1)- or DMSO-diluted (Figure 4.3) Rh-LP1 and Rh-LP2 for 16 h. (A) Final dilution into 
PBS/FBS (10%), (B) into in PBS/BSA (0.1%). IL-8 secretion was measured by ELISA. Error bars 
represent mean deviations of triplicates. 
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Figure 4.3 Dilution protocols for the preparation of lipopeptide solutions. First, lipopeptides were 
solubilized in DMSO as 1 mM stock solutions. Second, these stock solutions were either diluted 
1:20 with tert.-butyl alcohol/H2O (4:1) or DMSO. Third, a 1:500 dilution in PBS/BSA (0.1%) or 
PBS/FBS (10%) was subjected to fluorescence correlation spectroscopy or added 1:10 to THP-1 
cells in order to determine the agonistic activity. 
 
FCS experiments for aggregate detection of the differently diluted lipopeptides 
were conducted on the same day with aliquots of the same dilutions of 
lipopeptides in order to ensure maximum consistency of results. For any 
lipopeptide in any condition no large aggregates were detected (Figure 4.4).  
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Figure 4.4 Dilution dependent aggregation determined by fluorescence correlation 
spectroscopy. Tert.-Butyl alcohol/H2O (4:1) or DMSO diluted Rh-LP1 and Rh-LP2 were diluted 
1:500 in PBS/BSA (0.1%) as described in material/methods and subjected to fluorescence 
correlation spectroscopy. (A-D) Fluorescence count traces F(t) of 60 s measurements of Rh-LP1 
(A,C) and of Rh-LP2 (B,D) either treated with tert.-butyl alcohol/H2O (4:1) (A,B) or DMSO (C,D). 
Autocorrelation functions of Rh-LP1 (E) and Rh-LP2 (F).  
 
In the fluorescence count traces, such aggregates constitute themselves as 
large spikes of fluorescence and compromise the acquisition of autocorrelation 
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functions. The obtained count traces were characteristic for homogeneously 
solubilized molecules. Smooth autocorrelation functions with well defined 
diffusional autocorrelation times were obtained in all cases. However, for Rh-LP1 
diluted only in DMSO the autocorrelation function was right-shifted towards longer 
autocorrelation times in contrast to the tert.-butyl alcohol/H2O-diluted sample 
(Figure 4.4E). This finding indicates that the lipopeptide was present in aggregates 
of higher molecular weight. The autocorrelation functions of differently diluted Rh-
LP2 were indistinguishable from each other, consistent with their comparable 
biological activities (Figure 4.4F). All autocorrelation functions could be fitted with a 
formalism including only one diffusing component, yielding the diffusional 
autocorrelation times τD. As mentioned above, the autocorrelation function allows 
conclusions about the aggregation state of the fluorescent molecules. Only a 
substantial mass increase of the particles results in a detectable shift of the 
autocorrelation function.  
For Rh-LP1, treatment with tert.-butyl alcohol/H2O reduced the diffusional 
autocorrelation time to 200 µs compared to 350 µs for the DMSO-diluted sample 
(Figure 4.5A). For Rh-LP2 for both conditions a diffusional autocorrelation time of 
about 200 µs was determined corresponding to the one of the tert.-butyl 
alcohol/H2O-diluted Rh-LP1. Interestingly, while for the dilution into BSA and FBS-
containing buffers the general observations were the same for both lipopeptides, in 
detail the diffusional autocorrelation times differed (Figure 4.5B). For Rh-LP2 
diluted into FBS-containing buffer, for both dilution protocols the diffusional 
autocorrelation times were significantly longer, while for Rh-LP1 diluted directly 
from the DMSO stock solution, the diffusional autocorrelation time was shorter. 
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Figure 4.5 Diffusion times of fluorescently labeled lipopeptides determined by fluorescence 
correlation spectroscopy. Diffusional autocorrelation time (µs) of fluorescent labeled lipopeptides 
and FITC-BSA in (A) PBS/BSA (0.1%) or (B) PBS/FBS (10%) were obtained by fitting of the 
autocorrelation functions using the Confocor software. The values represent the median and 
standard deviation of the diffusion time of 10 measurement intervals of 60 s measurement time, 
each. 
 
In order to obtain information on the size of these particles, FCS measurements 
were also performed for fluorescein-labeled BSA serving as a molecular size 
reference. For BSA a diffusional autocorrelation time of 150 µs was obtained, 
indicating that in any case the lipopeptides were present as aggregates 
significantly exceeding the size of BSA. Binding of a single lipopeptide molecule to 
BSA would not be expected to result in such an increase in molecular size. BSA 
has a hydrodynamic radius of about 4 nm [239]. Assuming a globular shape, the 
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radius of the lipopeptide-containing particles should therefore be in the range of 5 
to 7 nm. Correlation of the FCS results with the induction of IL-8 expression 
therefore reveals a negative correlation of the size of the lipopeptide-containing 
particle and the biological activity. 
So far, following established protocols, lipopeptides had been diluted into 
protein-containing media. When lipopeptides, either diluted only with DMSO or 
with tert.-butyl alcohol/H2O, were diluted into BSA- and FBS-free PBS almost no 
agonistic activity was detected. In the fluorescence count trace large peaks were 
present, indicating the formation of large aggregates that were heterogeneous in 
size (Figure 4.6).  
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Figure 4.6 (A) Biological activity of Rh-LP1 and Rh-LP2 diluted in PBS without FBS and BSA in 
comparison to Rh-LP2 diluted in PBS/FBS (10%). (B) Fluorescence count trace of Rh-LP1 diluted 
into PBS alone. 
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Due to the heterogeneity of the size of the detected aggregates the calculation 
of the autocorrelation function was impossible.  
4.4 Discussion 
When testing different lipopeptides for their agonistic activity in a cellular assay, 
we observed for some compounds a strong dependence of the activity on the 
solvent applied during dilution onto working concentration. Especially dilution with 
tert-butyl alcohol treatment of some lipopeptides prior to the dilution into the cell 
containing medium significantly enhanced the agonistic activity. Aqueous buffers, 
required for cellular assays, force amphipathic molecules into an aggregated state 
which shields the hydrophobic moieties against the hydrophilic environment. For 
the in vitro testing of the agonistic activities of different amphipathic molecules, 
however, it is necessary to achieve comparability of the test scores. In this study 
we addressed the question if the aggregation state of a lipopeptides influences 
their agonistic activity and if dilution with different solvents results in different 
aggregation states of these amphiphilic molecules. 
So far, little has been known about the molecular mechanism of TLR2 activation 
by lipopeptides. Definition of the molecular state of these molecules once they 
encounter a target cell is the first step for dissecting the molecular events leading 
to receptor activation. The observation that for some analogues of the synthetic 
Pam3Cys lipopeptide the biological activity depended on the dissolution protocol 
prompted us to investigate whether these differences were due to differences in 
the molecular state, i. e. aggregation of these molecules. Solutions of fluorescently 
labeled lipopeptide analogues were analyzed by fluorescence correlation 
spectroscopy. Aggregates of similar size were obtained for both tested 
lipopeptides when the optimized dissolution protocol was employed. The finding 
that the autocorrelation functions could be fitted with one diffusive component 
indicates that these aggregates were not very heterogeneous in nature, however, 
it cannot be concluded that lipopeptides form well-defined oligomers. For 
polyethyleneimine-DNA complexes a very similar observation had been made 
[240]. 
Remarkably, in all cases the aggregates were larger in size than BSA. If no 
protein was present in the medium, very large and heterogeneous aggregates 
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were obtained. Apparently, the lipopeptide aggregates do not exist free in solution 
but associate with BSA or constituents of the FBS.  
For the TLR4-agonist LPS, it has been reported that aggregates bind to 
membrane-bound LBP leading to the activation of cells [230;241].  In addition to 
LBP, albumine is involved in the LPS-dependent activation of cells. Prior to the 
binding to LBP, aggregated LPS forms a complex with albumin and mediates its 
solubility in aqueous solutions [238]. The formation of large and heterogeneous 
aggregates in PBS without added proteins (Figure 4.6), suggests that serum 
components may exert a similar solubilizing function for lipopeptides.  
Several accessory molecules such as CD14 [44;150]  or LBP [242] in addition to 
TLRs contribute to the lipopeptide dependent activation of cells. The involvement 
of these proteins indicates for an incorporation of lipopeptides into membrane 
associated proteins. For our experiments, FBS constitute a source of these 
proteins and we observed that lipopeptides diluted into buffer containing FBS 
exhibited an enhanced activity in comparison to lipopeptides which were diluted in 
buffer only containing BSA. Nevertheless, the addition of BSA to PBS was 
sufficient to achieve a solubilization state of the lipopeptides that renders the 
lipopeptides biologically active and enables the acquisition of defined 
autocorrelation functions by FCS. This dissolution protocol therefore generates a 
basis for the analysis of structure-activity relationships of lipopeptides under highly 
controlled conditions.  
4.5 Materials and methods 
4.5.1 Reagents 
Standard chemicals were from Fluka (Deisenhofen, Germany) and Merck 
(Darmstadt, Germany). 1-Hydroxybenzotriazole, diisopropylethylamine, N,N´-
diisopropylcarbodiimide, piperidine, dichloromethane, dimethylformamide were 
from Fluka. FITC-labeled albumin was from Sigma (Taufkirchen, Germany). Fmoc-
amino acids were from Novabiochem (Läufelfingen, Switzerland), Senn Chemicals 
(Dielsdorf, Switzerland), and Orpegen Pharma (Heidelberg, Germany). Pam3Cys-
OH was from EMC microcollections GmbH (Tübingen, Germany). 
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4.5.2 Lipopeptides 
Pam3Cys-P5SIINFEKL-OH and Pam3Cys-P6FEDIYKN-OH and their 5(6)-
carboxytetramethylrhodamine labeled analogues Pam3Cys-
P5SIINFEK(NεTamra)L-OH and Pam3Cys-P6FEDIYK(NεTamra)N-OH were 
synthesized by fully automated solid phase chemistry [196] using the 
fluorenylmethoxycarbonyl-t-butyl strategy on TCP resins as described previously 
[243]. The N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteine residue 
was coupled to the free N-terminus of the resin-bound peptides in 
dimethylformamide/dichloromethane (1:1) with N,N´-diisopropylcarbodiimide/1-
hydroxybenzotriazol in three-fold excess within 3 h. The coupling was monitored 
by Kaiser test. The lipopeptides were cleaved off the resins and side chains 
deprotected with trifluoroacetic acid : phenol : ethanedithiol : thioanisole : water 
(96 : 2 : 1 : 2 : 1, v/w/v/v/v) for 3 h. The products were filtered from the resins, 
which were washed once with dichloromethane. The solvents were evaporated 
and lipopeptides were precipitated at -20°C by the addition of diethylether. The 
precipitates were washed twice by sonication with diethylether and were 
lyophilized from water : tert.-butyl alcohol (1 : 4, v/v). 
4.5.3 Labeling of lipopeptides with carboxytetramethylrhodamine 
For selective fluorescent labeling of the side chain of the lysine residue the 4-
methyltrityl group (Novabiochem) was deprotected by 0.5% TFA (v/v) in 
dichloromethane. After deprotection resin-bound lipopeptides were reacted with 3 
eq. of 5(6)-carboxytetramethylrhodamine, O-(benzotriazol-1-yl)-N,N,N',N'-
tetramethyluronium tetrafluoroborate,  1-hydroxybenzotriazol and 6 eq. N,N-
diisopropylethylamine in DMF for 16 h. Reactions were stopped by washing the 
resins five times each with DMF, methanol and diethyl ether. Completeness of 
labeling was confirmed by Kaiser-Test. The identity of defined lipopeptides was 
determined by electrospray mass spectrometry [244]. All biological and 
spectroscopic studies should be performed with freshly prepared solutions max 1 
h after performing the dilution protocol. 
THE STATE OF AGGREGATION DETERMINES THE BIOACTIVITY OF LIPOPEPTIDES 
_________________________________________________________________________ 
 
93
4.5.4 Dilution protocol 
Lipopeptide solutions were prepared using a three-step dilution protocol (Figure 
4.3): First, lipopeptides were solubilized to 1 mM stock solutions in DMSO. 
Second, these stock solutions were diluted 1:20 (v/v) either in tert.-butyl 
alcohol/H2O (4:1, v/v) or in DMSO. Third, for non fluorescent lipopeptides these 
dilutions were further diluted 1:500 in RPMI medium (PAN Biotech, Aidenbach, 
Germany) containing 10% FBS (PAN Biotech) and finally added 1:10 to the THP-1 
cell suspension. Fluorescent lipopeptides were diluted 1:500 in PBS, PBS 
containing 0.1% BSA or PBS containing 10% FBS. After incubation for 50 min at 
37°C on a shaker samples were used for fluorescence correlation spectroscopy or 
for stimulation of THP-1 cells. Lipopeptide concentrations were determined by 
UV/VIS-spectroscopy. For this purpose the DMSO-stock solution was diluted 
(1:500) in MeOH. Absorption was measured at a wavelength of 540 nm. 
Concentrations were calculated using a molar extinction coefficient of 95,000 
l/(mol⋅cm). 
4.5.5 Aggregate analysis by single molecule detection. 
FCS measurements were carried out on a ConfoCor2 fluorescence correlation 
spectroscope (Carl Zeiss, Jena, Germany) using a 400 µl sample volume in an 8-
well chambered coverslip (Nunc, Wiesbaden, Germany). Fluorescein fluorescence 
was excited using the 488 nm line of an argon-ion laser and fluorescence detected 
using a BP 505 – 550 nm band pass filter; Tamra fluorescence was excited using 
a 543 nm HeNe-laser and fluorescence was detected with a 550 - 600 nm 
bandpass filter. For each experimental condition every sample was subjected to 
10 measurement intervals of 60 s measurement time, each. Autocorrelation 
functions were calculated on-line using the ConfoCor 2 FCS software. 
Autocorrelations were fitted between 10 µs and 1 s with a formalism accounting for 
one diffusing species. For samples in which a large number of aggregates were 
present no defined autocorrelation functions could be obtained. Diffusion 
coefficients D were calculated from:  
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(ωxy = radius of the detection volume in the xy-plane, τD = diffusional 
autocorrelation time). ωxy was determined from τD of rhodamine-6-G (D = 2.5 · 10-6 
cm2 s-1).  
For PBS-diluted samples that exhibited signals originating from solution 
containing highly heterogeneous aggregates with strong heterogeneity evaluation 
of fluorescence fluctuations using autocorrelation analysis was not possible. 
4.5.6 Cell culture 
The human monocytic leukemia cell line THP-1 was obtained from the DSMZ 
(Braunschweig, Germany). The cells were cultured in RPMI 1640 medium 
supplemented with 10% FBS in a 5% CO2 humidified atmosphere at 37°C. Cells 
were passaged every third to fourth day.  
4.5.7 IL-8 ELISA 
THP-1 cells were suspended in RPMI medium containing 10% fetal calf serum 
and dispensed into 96-well culture plates at a cell density of 5 x 104 cells per 180 
µl of medium. The cells were then incubated for 1 h at 37°C in the incubator. 20 µl 
of the 1:500 diluted lipopeptides were then added to THP-1 cells and further 
incubated at 37°C for 16 h. Controls with peptide-free buffers containing equal 
amounts of DMSO and tert-butyl alcohol/H2O in RPMI (10% fetal calf serum), PBS, 
PBS containing 0.1% BSA or PBS containing 10% fetal calf serum were included 
in each assay. Cell free supernatants were collected and stored at –80°C prior to 
the ELISA. Maxi-sorb 96-well plates (Nunc, Wiesbaden, Germany) were coated for 
20 h with 100 µl per well of a solution of a mouse anti-human IL-8 antibody (clone 
G265-5, BDPharMingen, San Diego, USA) (1 µg/ml in PBS). After blocking with 
200 µl of PBS/4% BSA per well, the plates were incubated with 100 µl of culture 
supernatants diluted 1:2 in PBS/4% BSA for 1 h at room temperature. 
Subsequently, 100 µl per well of a solution of a biotinylated mouse anti-human IL-8 
antibody (clone G265-8, BDPharMingen) (0.5 µg/ml in PBS/4% BSA) was added 
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and incubated for 1 h, followed by a 1 h incubation with streptavidin horseradish 
peroxidase (Pierce, Bonn, Germany) (1:5,000 in PBS/4% BSA). For detection, the 
plates were incubated with 3,3´,5,5´-tetramethylbenzidine substrate (Pierce, 
Rockford, USA). The reaction was stopped by adding 100 µl H2SO4 (0.5 M) to 
each well and the absorbance was measured at 450 nm with a microplate reader 
(Molecular Devices SpectraMax 340, GMI, Albertville, USA). After each incubation, 
the plates were washed three times with PBS pH 7.2/0.2% Tween 20 (Sigma). 
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5 Lipolanthionine peptides act as inhibitors of TLR2-mediated  
IL-8 secretion 
The chapter was adapted from a manuscript submitted to Journal of Medicinal 
Chemistry. The author of this thesis performed all experiments shown in Figure 5.2 
to 5.5 Lipolanthionine peptides were synthesized and analysed by Dr. Tobias 
Seyberth.  
5.1 Summary 
Lipoproteins from Gram-positive and Gram-negative bacteria and from 
mycoplasma as well as shorter synthetic lipopeptide analogues activate cells of 
the innate immune system via Toll-like receptor TLR2/TLR1 or TLR2/TLR6 
heterodimers. For this reason, these compounds constitute highly active adjuvants 
for vaccines either admixed or covalently linked. The lanthionine scaffold has 
structural similarity with the S-[2,3-dihydroxypropyl]-cysteine core structure of 
lipopeptides. Therefore, lanthionine-based lipopeptide amides were synthesized 
and probed for activity as potential TLR2 agonists and antagonists. A collection of 
analytically defined lipolanthionine peptide amides exhibited an inhibitory effect of 
the TLR2-mediated IL-8 secretion when applied in high molar excess to the 
agonistic synthetic lipopeptide Pam3Cys-Ser-(Lys)4-OH. Analysis of structure-
activity relationships revealed the influence of the chirality of the two α-carbon-
atoms, chain lengths of the attached fatty acids and fatty amines and of the 
oxidation level of the sulphur atom on the inhibitory activity of the lipolanthionine 
peptide amides.  
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5.2 Introduction  
Lipoproteins are cell wall components of Gram-positive and Gram-negative 
bacteria [245;246] and mycoplasma [247;248].  The N-terminal cysteine residue of 
these bacterial membrane proteins is posttranslationally modified to S-[2,3-
dihydroxypropyl]-cysteine (Dhc) which is acylated by three or two fatty acids. 
Lipoproteins and synthetic analogues such as the water-soluble lipohexapeptide 
Pam3Cys-Ser-(Lys)4-OH [90]  stimulate B cell proliferation and possess very 
favorable adjuvant activities in the generation of T cell responses to vaccines 
[83;84;86;249;250]. 
Among PAMPs lipopeptides are the primary candidates for analysing the 
structure-activity relationships of immune modulators. The role of the peptide 
moiety, the number and structure of the fatty acids and the stereochemistry of 
lipopeptides based on Dhc for TLR activation have been analysed in great detail 
[94;251]. In contrast, variation of the Dhc core-structure has found little attention 
so far [252]. The apparent similarity of the scaffolds Dhc and lanthionine (Figure 
5.1) led us to the assumption that lanthionine-based lipopeptide amides might 
show TLR2 agonistic activities similar to those of Pam3Cys-
peptides [83;84;86;90;249;250] or, due to their structural differences, inhibitory 
activities.  
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Figure 5.1 Structures of the natural thioether amino acid scaffolds Dhc (A) and lanthionine (Lan) 
(B). Because of the structural relationship lanthionine is an interesting scaffold for lipopeptides with 
potential TLR2 agonistic or antagonistic activity. R1, R2 and R3 are long chain alkyl residues; R4 
correspond to the peptide moiety. 
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TLR agonists and antagonists are potential candidates for the treatment of 
various immune-associated diseases [253]. TLR2 antagonists have been 
suggested to have beneficial effects in chronic inflammation, acute inflammation, 
skin diseases such as acne, and treatment of sepsis. In order to explore these 
therapeutic options there is an imminent need for synthetically accessible TLR 
agonistic and antagonistic compounds. Recently it was demonstrated in a sepsis 
model that lethal shock-like syndromes could be prevented by treatment of mice 
with the TLR2 antagonistic antibody mAB T2.5 prior to lipopeptide or Bacillus 
subtilis challenge [110]. No synthetic low molecular weight compounds with 
inhibitory activity against TLR2 have been described so far. 
Lanthionine was first discovered in alkaline hydrolysates of wool. Moreover, this 
molecule was found in human hair, and keratin. In human lenses the photo-
oxidative degradation of cystine residues may also result in the formation of 
lanthionine, accompanied by protein cross-bridging that leads to increased tissue 
rigidity and hardening of the lens. Another highly interesting natural occurrence of 
lanthionine is the class of bioactive lantibiotics [254].  
For the synthesis of lipolanthionine a new preparation method for N,N-bis-
(Fmoc)-lanthionine with orthogonally protected carboxy groups was formulated by 
Seyberth et al. (2005). A representative collection of lipolanthionine peptides with 
variations in the length of the fatty acid, the fatty amine as well as the oxidation 
level of the sulfur and the stereoconfigurations was tested for biological activity, 
revealing an ability of these compounds to inhibit the TLR2-mediated IL-8 
secretion.  
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5.3 Results 
5.3.1 Structure-activity relationships  
A representative collection of analytically defined single lipolanthionine peptide 
amides (Table 5.1) was tested for agonistic activity and for their ability to inhibit the 
TLR2-mediated IL-8 secretion.  
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Figure 5.2 Core-structure of the synthesized lipolanthionine peptide amides: Definition of the 
residues and abbreviations for Table 5.1 (R1, R2 alkyl chains / y = 0; sulfide; y = 1, sulfoxide; y = 2 
sulfone / configurations Cα2,Cα6: 2R,6R; 2R,6S; 2S,6R; 2S,6S / X = NH, O). 
 
Table 5.1 Lipolanthionine peptides test for agonistic and inhibitory activity. 
 R1 X R2 SOy Cα2 Cα6 
1 C6H13 NH C13H27 0 R R 
2 C8H17 NH C13H27 0 R R 
3 C10H21 NH C13H27 0 R R 
4 C12H25 NH C13H27 0 R R 
5 C14H29 NH C13H27 0 R R 
6 C16H33 NH C13H27 0 R R 
7 C18H37 NH C13H27 0 R R 
10 C16H33 NH C5H11 0 R R 
11 C16H33 NH C7H15 0 R R 
12 C16H33 NH C9H19 0 R R 
13 C16H33 NH C11H23 0 R R 
LIPOLANTHIONINE PEPTIDES ACT AS INHIBITORS OF TLR2-MEDIATED IL-8 SECRETION 
_________________________________________________________________________ 
 
101
14 C16H33 NH C15H31 0 R R 
15 C16H33 NH C17H35 0 R R 
16 C16H33 NH C19H39 0 R R 
20 C16H33 NH C13H27 0 R S 
21 C16H33 NH C13H27 0 S R 
22 C16H33 NH C13H27 0 S S 
30 H O C13H27 0 R R 
31 H O C13H27 0 R S 
32 H O C13H27 0 S R 
33 H O C13H27 0 S S 
40 C16H33 NH C15H31 1 R R 
41 C16H33 NH C15H31 2 R R 
 
To test the inhibitory activity of the lipolanthionine peptides, the well-studied 
agonist Pam3Cys-Ser-(Lys)4-OH was used for stimulation of THP-1 cells. The 
synthesized lipolanthionine compounds enabled the analysis of the structure-
activity relationships for the (i) fatty amine chain length, (ii) fatty acid chain length, 
(iii) stereochemical properties and (iv) the oxidation level of the sulphur. 
First, the influence of the fatty amine chain length was investigated using the 
derivatives based on the bis-myristoylated (2R,6R)-lanthionine lipopeptide amides 
(1-7). At concentrations of 25 µM only for the hexylamine derivative (1) a weak 
agonistic activity was observed. 
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Figure 5.2 Inhibitory activities of Myr2Lan(R1)-SK4-NH2 with varying fatty amine residue R1. THP-
1 cells were incubated with lipolanthionine peptides (25 µM) in the absence or presence of the 
agonistic lipohexapeptide Pam3Cys-SK4-OH (50 nM) for 5 h. The secretion of IL-8 was detected by 
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ELISA in cell free supernatants. The Pam3Cys-SK4-OH induced IL-8 secretion is shown in relation 
to a sample that was incubated with Pam3Cys-SK4-OH in the presence of the same amount of 
solvent as the lipolanthionine-containing samples. Error bars represent the standard deviation of 
triplicates in one representative experiment.  
 
Interestingly, except for the hexylamine derivative (1) all analogues of 
lipolanthionine peptide amides exhibited a pronounced and comparable TLR2 
inhibitory activity (Figure 5.2). When applied in a 500-fold excess (25 µM) over the 
highly potent Pam3Cys-Ser-(Lys)4-OH TLR2 agonist (50 nM), IL-8 expression was 
reduced by 48 to 65 %. Therefore, given a minimum length of 8 carbon atoms, the 
length of the fatty amine chain seemed to be of minor significance. Except for the 
octadecylamine derivative (7) no cell toxic properties were observed at the tested 
concentration as determined by MTT-test. The derivative containing the 
hexadecylamine residue was arbitrarily selected for further tests. 
Next the influence of the variation of the amide-bound fatty acid moieties was 
studied. In this case, only for the caprylic acid derivative (C-8, 11) an agonistic 
activity was observed. The derivatives containing lauric (C-12, 13), myristic (C-14, 
6) and palmitic acid (C-16, 14) had the highest inhibitory effect on the lipopeptide-
induced IL-8 secretion (Figure 5.3). The analogues with short fatty acids (C-6 – C-
10, 10-12) exhibited less inhibitory activities. 
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Figure 5.3 Inhibitory activities of (R2)2Lan(Hda)-SK4-NH2 with varying fatty acid residue R2. THP-
1 cells were incubated with lipolanthionine peptides (25 µM) in the absence or presence of 
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Pam3Cys-SK4-OH (50 nM) for 5 h. The secretion of IL-8 was detected by ELISA in cell-free 
supernatants. 
 
For two of the most active inhibitors (6, 14), the concentration dependence of 
the inhibitory activity was determined. For both compounds a concentration-
dependent decrease in IL-8 expression was observed (Figure 5.4).  
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Figure 5.4 Concentration dependence of the inhibitory activity of Myr2Lan(Hda)-SK4-NH2 (6) and 
Pam2Lan(Hda)-SK4-NH2 (14). THP-1 cells were incubated with lipolanthionine peptides (0, 0.78, 
1.56, 3.13, 6.25, 12.5, 25 µM) in the presence of Pam3Cys-SK4-OH (50 nM) for 5 h. The secretion 
of IL-8 was detected by ELISA in cell free supernatants. Error bars represent the standard 
deviation of triplicates. 
 
For the myristic acid derivative, IL-8 expression was reduced by up to 86% for 
the palmitic acid derivative by up to 68%. Both compounds exhibited IC50 values of 
about 5 µM. However, the inhibitory activity of compounds 17 and 18 varied 
between several experiments (38, 18 and 14% residual activity for compound 17, 
respectively 30 and 42% for compound 18).  
The agonistic activity of Pam3Cys-Ser-(Lys)4-OH and even of lipopeptide 
vaccines is dependent on the configuration of the S-glyceryl-cysteine scaffold 
[255]. Therefore the four stereoisomers of the bis-myristoylated hexadecylamide 
derivative, the most active inhibitor identified so far were tested. The agonistic 
activity negatively correlated with the inhibitory activity. The (2R,6R)-lanthionine 
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peptide showed the highest inhibitory activity, closely followed by the 
(2S,6R) derivative (6 and 21; Figure 5.5). 
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Figure 5.5 Dependence of the inhibitory activities of Myr2Lan(Hda)-SK4-NH2 (17) on the 
configuration of the lanthionine scaffold. THP-1 cells were incubated with lipolanthionine peptides 
(25 µM) in the absence or presence of Pam3Cys-SK4-OH (50 nM) for 5 h. The secretion of IL-8 was 
detected by ELISA in cell-free supernatants. Error bars represent the standard deviation of 
triplicates. For inhibition high bars indicate low activity, while for agonism high bars indicate high 
activity.  
 
In contrast, a change of the configuration in the C-6 stereocenter led to a loss of 
the inhibitory and to an increase of the agonistic activity. The agonistic activity of 
the (2R,6S) was higher than that of the (2S,6S) derivative. Therefore, only the 
configuration of C-6 strongly influences the TLR2 inhibitory activity of the 
compounds whereas the configuration at C-2 seems to be of minor significance. 
Lipolanthionine peptide amides containing free carboxy functions (30-33) were 
unable to suppress the Pam3Cys-Ser-(Lys)4-OH-induced IL-8 secretion. 
Interestingly, the methyl ester derivatives possessed cell toxic properties (MTT-
test, data not shown). The Pam2LanHda-Ser-(Lys)4-NH2 oxides (40 and 41) 
showed no significant alteration of the observed inhibitory effect (data not shown). 
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5.4 Discussion 
So far, analyses of structure-activity relationships of the well characterized 
lipopeptide and highly active TLR2 agonist Pam3Cys-Ser-(Lys)4-OH have focused 
mainly on the periphery of the natural core scaffold (Dhc), i. e. variations of the 
peptide and/or of the fatty acids. In order to vary the scaffold, we substituted the 
Dhc by the structurally related thioether amino acid lanthionine. The lanthionine 
scaffold possesses the same number of functional groups, suitable for the 
introduction of structural diversity for lipopeptide synthesis, as the Dhc scaffold. 
Two lipolanthionine peptide amides were tested for their capacity to influence the 
IL-8 secretion induced by the TLR2 agonist Pam3Cys-Ser-(Lys)4-OH. These in 
vitro tests revealed concentration-dependent and saturable TLR2 inhibitory rather 
than agonistic activities of the lipolanthionine peptides.  
Detailed analyses of the structure-activity relationship for the fatty acid and fatty 
amine moieties were conducted for the (2R,6R) configuration. The chain length of 
the amide-bound fatty acid had a strong influence on the activity, whereby the 
myristic acid derivative (6) was the most effective inhibitor of the lipopeptide 
induced IL-8 secretion. In contrast, the chain length of the amide-bound fatty 
amine residue had no influence on the inhibitory activity for chain lengths from C-8 
to C-16 (2-6). The C-6 derivative (10) exhibited some agonistic activity. 
The configuration at the C-6 position of the lanthionine proved to be crucial for 
inhibitory activity whereas the C-2 configuration showed little influence. In 
conclusion, the lipolanthionine peptide amide (2R,6R)-Myr2LanHda-Ser-(Lys)4-NH2 
(6) exhibited the strongest TLR2 inhibitory activity. 
Several possibilities exist in which way the lipolanthionine peptide amides might 
influence the TLR2-mediated IL-8 secretion. First, the inhibitor may interact with 
the agonist preventing receptor recognition and initiation of signal transduction 
[168]. Second, the inhibitor may influence the TLR2 and/or a coreceptor directly, 
by interacting with the respective ligand binding site. Third, the lipolanthionine 
peptides could inhibit the assembly of the TLR2 receptor complex by integrating 
into cell membrane domains like lipid rafts. For TLR4 it was demonstrated that 
LPS induces the co-clustering of CD14 and TLR4 in the lipid rafts [256;257]. 
Recently it was shown that oxidized phospholipid products inhibited the LPS-
induced translocation of TLR4 to lipid rafts [258]. It was also reported, that n-3 
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unsaturated fatty acids caused the alteration of fatty acid composition in 
membrane lipid rafts, resulting in the inhibition of T cell activation [259].  
A direct inhibition by selective blocking of the TLR2 receptor and/or either the 
TLR1 or TLR6 coreceptor seems to be rather unlikely, since the lipolanthionine 
peptides also inhibited the LPS-induced, TLR4-mediated IL-8 secretion (data not 
shown). 
On the other hand, the inhibitory potential of the lipolanthionine peptides was 
strongly dependent on the configuration of the lanthionine C-6 position, an 
observation that favours a mechanism of inhibition based on the interaction with a 
receptor molecule. It is moreover remarkable that the agonistic activity of the 
lanthionine peptides negatively correlated with their inhibitory activity. Therefore, a 
non-specific mode of action by insertion of the lipolanthionine peptides into 
membrane domains such as lipid rafts seems to be unlikely. Instead of directly 
interacting with any TLR, the lipolanthionine peptides may bind to CD14, a 
coreceptor which is shared by LPS and lipopeptides for activation of their 
respective TLR [44]. Still, the high concentrations necessary for the inhibitory 
activity of the lipolanthionine peptides suggest a direct interaction with the 
agonists. For example, the agonist Pam3Cys-Ser-(Lys)4-OH might be integrated 
into micelles composed of lipolanthionine peptides. Future studies will have to 
elucidate whether the lipolanthionine peptide-mediated IL-8 inhibition follows one 
of the above-described mechanisms. 
 
5.5 Materials and methods 
5.5.1 Reagents 
Lipolanthinonine peptides were synthesized by Tobias Seyberth. Standard 
chemicals were from Fluka (Deisenhofen, Germany) and Merck (Darmstadt, 
Germany). Pam3Cys-Ser-(Lys)4-OH was from EMC microcollections GmbH 
(Tübingen, Germany). 
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5.5.2 Cell culture 
The human myelomonocytic cell line THP-1 (ATCC number: TIB-202) was 
obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen 
(DSMZ) (Braunschweig, Germany). The cells were cultured in RPMI 1640 medium 
(PAN Biotech, Aidenbach, Germany) supplemented with 10% FCS (PAN Biotech) 
in a 5% CO2 humidified atmosphere at 37°C. Cells were passaged every third to 
fourth day.  
5.5.3 IL-8 ELISA 
THP-1 cells were dispensed into 96-well culture plates at a cell density of 4 x 104 
cells per 200 µL of medium per well. Stock solutions of lipolanthionine peptides 
and Pam3Cys-SK4-OH (EMC microcollections, Tübingen, Germany) in DMSO 
were prepared at a concentration of 10 mM. Cells were incubated with 
lipolanthionine peptides at the indicated concentrations for 10 min at 37°C. 
Controls with lipolanthionine-free medium containing equal amounts of DMSO 
were included in each assay. The agonist Pam3Cys-SK4-OH was added to the 
samples at a concentration of 50 nM. After a further incubation for 5 h at 37°C cell-
free supernatants were collected and stored at -80°C prior to the quantification of 
IL-8 secretion by matched-pair ELISA (clone G265-5 and clone G265-8, 
BDPharMingen, San Diego, USA) according to the protocol provided by the 
manufacturer. 
5.5.4 Cell viability assay 
Cell viability was measured using the colorimetric 3-(4,5-dimethyl thiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) dye reduction assay. THP-1 cells were 
treated with the corresponding lipolanthionine peptides and Pam3Cys-SK4-OH for 
5 h (see above) and after removing 120 µl of the supernatant for ELISA analysis, 
cells were incubated with MTT (Sigma) at a concentration of 1 mg/ml for 4 h. The 
formazan product was solubilized with SDS (10% (m/v) in 10 mM HCl). The 
fraction of viable cells was determined by measuring the absorbance of each 
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sample at 570 nm relative to the absorbance of untreated control cells using the 
microplate reader. 
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6 Conclusions 
The successful treatment of patients with sepsis and septic shock might be 
hampered by the outstanding immune stimmulating properties of bacterial cell wall 
components, such as lipopeptides and lipopolysaccharides. Injections of only 
nanogram quantities of endotoxin are sufficient to evoke systemic inflammatory 
responses in humans and up to now, efforts to efficiently block these properties in 
vivo were insufficient.  
This work presents (i) novel agents that block lipopolysaccharide- and 
lipopeptide-induced TLR activation (ii) the identification of a LPS-binding domain of 
human CD14, (iii) a novel FRET-based LPS-sensing element (iv) investigations of 
lipopeptide aggregation as well as (v) a dilution protocol to reliably test 
lipopeptides in cellular assays. 
Chapter 2 and 5 of the thesis deal with the identification of molecules that 
interfere with LPS- and lipopeptide-induced cytokine secretion. Several 
possibilities exist to generate inhibititory molecules, such as random screening of 
compound libraries, rational design of inhibitors using receptor ligands as 
templates, or by mapping proteins that are critically involved in signal generation 
onto small peptides or peptidomimetics.  
The latter possibility was selected by using CD14, a central PRR in innate 
immuity, as a template for the generation of 20-peptides. The CD14-derived 
peptides were tested for their ability to inhibit the cytokine secretion of LPS-
stimulated monocytes. One peptide of this screen was found to bind and neutralize 
LPS. In contrast to formerly identified LPS-binding and -neutralizing peptides, 
hydrophobic residues were shown to be critical for this activity of the CD14-
peptide, and, as identified by site-directed mutagenesis, for the LPS-binding 
capacity of the entire protein. Therefore, the combination of peptide chemistry with 
cell biology and molecular biology enabled the identification of a novel ligand 
binding pocket as well as of specific residues involved in the LPS binding of 
human CD14. Interestingly, as revealed by comparison with the crystal structure of 
human CD14, this binding site is located in the interior of the protein. 
 The major purpose for the design of LPS-binding and –neutralizing peptides 
derived from CD14 was their potential application as drugs for the treatment of 
sepsis and septic shock. The CD14-derived peptides exhibited an IC50 value in 
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vitro in the low µM range which corresponds to that of other LPS-neutralizing 
peptides. However, the CD14-peptides lack to completely block the agonistic 
activity of LPS. In addition, highly charged analogues of the native sequence 
exhibited cell lytic as well as immune stimulating properties at concentrations 
higher than 5 µM. Despite of these limitations, the ability of CD14-derived peptides 
to encounter sepsis and septic shock in vivo has been investigated using the 
septic model of galactosamine-sensitized mice. Neither the peptide corresponding 
to the native sequence nor the analogue with enhanced solubility inhibited the 
LPS-induced death of the animals but rather enhanced the mortality of the mice. 
Interestingly, lethality was exclusively observed when the peptides were 
administered intraperitoneally in the presence of LPS. This effect might be due to 
the property of cationic peptides to amplify the immune-stimulatory properties of 
LPS. These and other attributes of peptide-based drugs, such as short half times 
in serum, poor transport properties from the intestine to the blood and across the 
blood-brain barrier, as well as rapid excretion through the liver and/or kidney might 
limit the applicability of the CD14-derived peptides and LPS-neutralizing peptides 
in general as drugs for the treatment of sepsis. Still, the CD14-derived peptides 
and the knowledge of their exact molecular mechanism of action may represent a 
starting point for the rational design of peptidomimetics and non-peptide 
analogues that overcome these limitations.  
Sepsis is usually induced by a mixture of various microorganisms rather than 
one pathogen and therefore LPS neutralization might be insufficient in most cases 
of sepsis. Additionally, LPS neutralization may be effective only in a very early 
phase of sepsis and may come too late at a time when multi-organ failure is 
already in progress. For these reasons, LPS-neutralizing peptides might be 
effective in preventing sepsis especially when applied together with agents that 
release LPS from the bacterial cell wall, as is the case for many antibiotics. 
Based on the LPS-binding peptide from CD14 a fluorescence-based LPS-
sensing element was designed and applied for LPS-detection in vitro. The sensing 
element containing the native sequence (CD14 (81-100)) did not enable specific 
recognition of LPS, because several other lipids evoked signals that were almost 
comparable to that evoked by LPS. However, when two different fluorescently 
labeled peptides with distinct physicochemical properties were combined and the 
data analysed in a way that considered the several aspects of characteristic 
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spectral changes evoked by the individual lipid compounds, specificity for LPS was 
achieved in the concentration range between 5 to 50 µM of ligand.  
In contrast to LPS, little is known whether the activity of lipopeptides is 
influenced by their aggregation state. For LPS, aggregates activate cells more 
efficiently than single molecules and several plasma and cellular proteins are 
required for the activation of cells by these complexes. As shown in chapter 4, the 
agonistic properties of some lipopeptides were highly dependent on the dissoluon 
protocol. Fluorescence correlation spectroscopy with fluorescently labeled 
analogues revealed that the solvent dependent activity was due to the property of 
the lipopeptides to form aggregates. Dilution into protein- and serum-free buffers 
led to a complete loss of activity due to formation of large and highly 
heterogeneous aggregates. In contrast, dilution into BSA- or serum-containing 
buffers strongly reduced the size of the aggregates. This indicates for an 
interaction of lipopeptides with serum compounds. Moreover, peptide-dependent 
differences in aggregate formation and activity were eliminated by introducing an 
additional dilution step in tert.-butyl alcohol/H2O (4:1). Due to fact that the dilution-
dependent activity might compromise biological screens these results are highly 
relevant for analyzing structure-activity relationships of lipopeptide-dependent 
TLR2 activation and contribute to a better understanding in which way the 
aggregation state of lipopeptides is critical for TLR2 activation. 
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